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A B S T R A C T
Background
Tuberculosis is a leading cause of infectious disease-related death and is one of the top 10 causes of death worldwide. The World Health
Organization (WHO) recommends the use of specific rapid molecular tests, including Xpert MTB/RIF or Xpert Ultra, as initial diagnostic
tests for the detection of tuberculosis and rifampicin resistance in people with signs and symptoms of tuberculosis. However, the WHO
estimates that nearly one-third of all active tuberculosis cases go undiagnosed and unreported. We were interested in whether a single
test, Xpert MTB/RIF or Xpert Ultra, could be useful as a screening test to close this diagnostic gap and improve tuberculosis case detection.
Objectives
To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra for screening for pulmonary tuberculosis in adults, irrespective of signs or
symptoms of pulmonary tuberculosis in high-risk groups and in the general population. Screening "irrespective of signs or symptoms"
refers to screening of people who have not been assessed for the presence of tuberculosis symptoms (e.g. cough).
To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra for detecting rifampicin resistance in adults screened for tuberculosis,
irrespective of signs and symptoms of pulmonary tuberculosis in high-risk groups and in the general population.
Search methods
We searched 12 databases including the Cochrane Infectious Diseases Group Specialized Register, MEDLINE and Embase, on 19 March
2020 without language restrictions. We also reviewed reference lists of included articles and related Cochrane Reviews, and contacted
researchers in the field to identify additional studies.
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Selection criteria
Cross-sectional and cohort studies in which adults (15 years and older) in high-risk groups (e.g. people living with HIV, household contacts
of people with tuberculosis) or in the general population were screened for pulmonary tuberculosis using Xpert MTB/RIF or Xpert Ultra.
For tuberculosis detection, the reference standard was culture. For rifampicin resistance detection, the reference standards were culture-
based drug susceptibility testing and line probe assays.
Data collection and analysis
Two review authors independently extracted data using a standardized form and assessed risk of bias and applicability using QUADAS-2.
We used a bivariate random-eJects model to estimate pooled sensitivity and specificity with 95% credible intervals (CrIs) separately for
tuberculosis detection and rifampicin resistance detection. We estimated all models using a Bayesian approach. For tuberculosis detection,
we first estimated screening accuracy in distinct high-risk groups, including people living with HIV, household contacts, people residing in
prisons, and miners, and then in several high-risk groups combined.
Main results
We included a total of 21 studies: 18 studies (13,114 participants) evaluated Xpert MTB/RIF as a screening test for pulmonary tuberculosis
and one study (571 participants) evaluated both Xpert MTB/RIF and Xpert Ultra. Three studies (159 participants) evaluated Xpert MTB/RIF
for rifampicin resistance. FiLeen studies (75%) were conducted in high tuberculosis burden and 16 (80%) in high TB/HIV-burden countries.
We judged most studies to have low risk of bias in all four QUADAS-2 domains and low concern for applicability.
Xpert MTB/RIF and Xpert Ultra as screening tests for pulmonary tuberculosis
In people living with HIV (12 studies), Xpert MTB/RIF pooled sensitivity and specificity (95% CrI) were 61.8% (53.6 to 69.9) (602 participants;
moderate-certainty evidence) and 98.8% (98.0 to 99.4) (4173 participants; high-certainty evidence). Of 1000 people where 50 have
tuberculosis on culture, 40 would be Xpert MTB/RIF-positive; of these, 9 (22%) would not have tuberculosis (false-positives); and 960 would
be Xpert MTB/RIF-negative; of these, 19 (2%) would have tuberculosis (false-negatives).
In people living with HIV (1 study), Xpert Ultra sensitivity and specificity (95% CI) were 69% (57 to 80) (68 participants; very low-certainty
evidence) and 98% (97 to 99) (503 participants; moderate-certainty evidence). Of 1000 people where 50 have tuberculosis on culture, 53
would be Xpert Ultra-positive; of these, 19 (36%) would not have tuberculosis (false-positives); and 947 would be Xpert Ultra-negative; of
these, 16 (2%) would have tuberculosis (false-negatives).
In non-hospitalized people in high-risk groups (5 studies), Xpert MTB/RIF pooled sensitivity and specificity were 69.4% (47.7 to 86.2) (337
participants, low-certainty evidence) and 98.8% (97.2 to 99.5) (8619 participants, moderate-certainty evidence). Of 1000 people where 10
have tuberculosis on culture, 19 would be Xpert MTB/RIF-positive; of these, 12 (63%) would not have tuberculosis (false-positives); and
981 would be Xpert MTB/RIF-negative; of these, 3 (0%) would have tuberculosis (false-negatives).
We did not identify any studies using Xpert MTB/RIF or Xpert Ultra for screening in the general population.
Xpert MTB/RIF as a screening test for rifampicin resistance
Xpert MTB/RIF sensitivity was 81% and 100% (2 studies, 20 participants; very low-certainty evidence), and specificity was 94% to 100%, (3
studies, 139 participants; moderate-certainty evidence).
Authors' conclusions
Of the high-risks groups evaluated, Xpert MTB/RIF applied as a screening test was accurate for tuberculosis in high tuberculosis burden
settings. Sensitivity and specificity were similar in people living with HIV and non-hospitalized people in high-risk groups. In people living
with HIV, Xpert Ultra sensitivity was slightly higher than that of Xpert MTB/RIF and specificity similar. As there was only one study of Xpert
Ultra in this analysis, results should be interpreted with caution. There were no studies that evaluated the tests in people with diabetes
mellitus and other groups considered at high-risk for tuberculosis, or in the general population.
P L A I N   L A N G U A G E   S U M M A R Y
How accurate are sputum Xpert tests for screening for active pulmonary tuberculosis and rifampicin resistance in adults whether
or not they have tuberculosis symptoms?
Why is using Xpert tests to screen for pulmonary tuberculosis important?
Tuberculosis is the leading cause of infectious disease-related death and one of the top 10 causes of death worldwide. The World Health
Organization (WHO) recommends using specific rapid tests as initial tests for diagnosing tuberculosis and rifampicin resistance in people
with signs and symptoms of tuberculosis. However, the WHO estimates that nearly one-third of all active tuberculosis cases go undiagnosed
and unreported. Not recognizing tuberculosis when it is present (a false negative test result) may result in illness and death and an increased
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
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risk of infecting others. An incorrect diagnosis of tuberculosis (false-positive result) may mean that people are given antibiotics when there
is no benefit to be gained.
What is the aim of this review?
To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra as screening tests for pulmonary tuberculosis and rifampicin resistance in adults
whether or not they have tuberculosis symptoms (such as cough, fever, weight loss, and night sweats). We were interested in how the tests
worked in groups at high risk for tuberculosis, including people living with HIV (PLHIV), household contacts of people with tuberculosis,
miners, people residing in prisons, people with diabetes, and in the general public.
What was studied in this review?
Xpert MTB/RIF and Xpert Ultra are rapid tests for simultaneously diagnosing tuberculosis and rifampicin resistance. We combined study
results to determine:
- sensitivity: people with tuberculosis (rifampicin resistance) correctly diagnosed as having the condition.
- specificity: people without tuberculosis (rifampicin resistance) correctly identified as not having the condition.
The closer sensitivity and specificity are to 100%, the better the test.
What are the main results in this review?
Twenty-one studies: 18 studies (13,114 participants) evaluated Xpert MTB/RIF as a screening test for pulmonary tuberculosis and one study
(571 participants) evaluated both Xpert MTB/RIF and Xpert Ultra. Three studies (159 participants) evaluated Xpert MTB/RIF for rifampicin
resistance.
For every 1000 people tested, if 50 had tuberculosis according to the reference standard:
PLHIV
- Xpert MTB/RIF (12 studies):
· 40 people would test positive, including 9 without tuberculosis (62% sensitivity)
· 960 people would test negative, including 19 with tuberculosis (99% specificity)
- Xpert Ultra (1 study):
· 53 people would test positive, including 19 without tuberculosis (69% sensitivity)
· 947 people would test negative, including 16 with tuberculosis (98% specificity)
For every 1000 people tested, if 10 had tuberculosis according to the reference standard:
Other high-risk groups combined
- Xpert MTB/RIF (5 studies):
· 19 people would test positive, including 12 without tuberculosis (69% sensitivity)
· 981 people would test negative, including 3 with tuberculosis (99% specificity)
For detection of rifampicin resistance, Xpert MTB/RIF sensitivity was 81% and 100% (2 studies) and specificity was 94% to 100% (3 studies).
How reliable are the results of the studies in this review?
In the included studies, the reference standards for diagnosing pulmonary tuberculosis (culture) and rifampicin resistance (drug
susceptibility testing) are likely to have been reliable methods for deciding whether patients really had the conditions. We were fairly
confident in the results for Xpert MTB/RIF in PLHIV, and less so for other high-risk groups. Not enough people have been studied to be
confident about the results for Xpert Ultra or for detection of rifampicin resistance.
Who do the results of this review apply to?
Studies were mainly performed in high tuberculosis and high HIV burden settings. No studies evaluated the tests in people with diabetes
mellitus or the general population.
What are the implications of this review?
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
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In PLHIV, Xpert MTB/RIF as a screening test was accurate for tuberculosis in high tuberculosis burden settings. In high-risk groups, Xpert
MTB/RIF may assist in identifying tuberculosis, but the certainty of evidence is low. In PLHIV, Xpert Ultra sensitivity was slightly higher than
that of Xpert MTB/RIF and specificity similar based on one study. There were few studies and few people tested for rifampicin resistance
and no studies that evaluated the tests in people with diabetes or in the general population.
How up-to-date is this review?
19 March 2020.
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
or symptoms (Review)



















































































































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Xpert MTB/RIF as a screening test for pulmonary tuberculosis in people living with HIV and non-hospitalized people in high-
risk groups
Review question: what is the accuracy of Xpert MTB/RIF and Xpert Ultra for screening for pulmonary tuberculosis in adults irrespective of signs or symptoms of pulmonary
tuberculosis?
Patients/population: people living with HIV and non-hospitalized people in high-risk groups
Setting: community and primary care facilities
Index tests: Xpert MTB/RIF and Xpert Ultra; role: screening test
Threshold for index tests: an automated result is provided
Reference standards: solid or liquid culture
Studies: cross-sectional and cohort studies
Number of results per 1000 patients tested (95% CI)Index test,
population








True positives 3 (3 to 3) 31 (27 to 35) 62 (54 to 70)Pooled sensitivity
61.8% (53.6 to 69.9)
602 (12)
False negatives 2 (2 to 2) 19 (15 to 23) 38 (30 to 46)
⨁⨁⨁ ◯
Moderatea,b





98.8% (98.0 to 99.4)
4173 (12)
False positives 10 (10 to 20) 9 (9 to 19) 9 (9 to 18)
⨁⨁⨁⨁
High
True positives 3 (3 to 4) 34 (28 to 40) 69 (57 to 80)Sensitivity
69% (57 to 80)
68 (1)
False negatives 2 (1 to 2) 16 (10 to 22) 31 (20 to 43)
⨁◯◯◯c,d
Very low





98% (97 to 99)
503 (1)
False positives 20 (10 to 30) 19 (9 to 28) 18 (9 to 27)
⨁⨁⨁◯c
Moderate
        Prevalence 0.5% Prevalence 1% Prevalence 2% Certainty of
the evidence
(GRADE)






















































































































































































































True negatives 983 (967 to 990) 978 (962 to 985) 968 (953 to 974)Pooled specificity 98.8%
(97.2 to 99.5)
8619 (5)
False positives 12 (5 to 28) 12 (5 to 28) 12 (5 to 27)
⨁⨁⨁◯e
Moderate
Abbreviations: CI: confidence interval; CrI: credible interval; IQR: interquartile range.
Prevalence estimates were suggested by the WHO Global TB Programme. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 12.5% (IQR 9.8%
to 15.4%). For Xpert Ulta, the prevalence of tuberculosis was 11.9%.
95% credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity; 95% confidence intervals were estimated for true positives,
false negatives, true negatives, and false positives.
Explanations
aMost studies were conducted in high-tuberculosis burden settings. Applicability to settings with lower tuberculosis prevalence comes with some uncertainty. This was a
judgment; we did not downgrade for indirectness.
bFor individual studies, sensitivity ranged from 43% to 100%. We thought that heterogeneity could be explained in part by the percentage of patients with tuberculosis symptoms,
diJerences in CD4 count, and hospitalized versus outpatient status. We downgraded one level for inconsistency.
cOnly one study contributed to this estimate. South Africa is the only country represented. Applicability to other settings comes with some uncertainty. We downgraded one
level for indirectness.
dThe 95% CI is wide. There was a low number of participants contributing to the analysis for the observed sensitivity. We downgraded two levels for imprecision.
e"Non-hospitalized people in high risk groups" is a broad category comprising adults with multiple geographic, occupational, environmental, clinical, and behavioral risk factors
for tuberculosis. Studies contributing to this pooled estimate included household contacts of persons with tuberculosis, adults in prison, and miners. There is some uncertainty
associated with applicability to other high-risk groups. Additionally, one of the studies included a small number of children (age < 15) in the screened population, which deviates
from the intended study population. We downgraded one level for indirectness.
fSensitivity estimates ranged from 33% to 100%. We thought this variability could partly be explained by the diJerent high-risk groups in this analysis. We downgraded one level
for inconsistency.
gThe 95% Crl is wide. We thought the 95% CrI around true positives and false negatives would likely lead to diJerent decisions depending on which limits are assumed. As we
had already downgraded for inconsistency, we did not downgrade further for imprecision.
GRADE certainty of the evidence.
High: we are very confident that the true eJect lies close to that of the estimate of the eJect.
Moderate: we are moderately confident in the eJect estimate: the true eJect is likely to be close to the estimate of the eJect, but there is a possibility that it is substantially
diJerent.
Low: our confidence in the eJect estimate is limited: the true eJect may be substantially diJerent from the estimate of the eJect.
Very low: we have very little confidence in the eJect estimate: the true eJect is likely to be substantially diJerent from the estimate of eJect.
The results presented in this table should not be interpreted in isolation from the results of individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 2.   Xpert MTB/RIF for detecting rifampicin resistance for high-risk groups
Review question: what is the accuracy of Xpert MTB/RIF and Xpert Ultra for screening for rifampicin resistance in adults irrespective of signs or symptoms of pulmonary tu-
berculosis?
Patients/population: people in high-risk groups
Setting: community and primary care facilities
Index tests: Xpert MTB/RIF and Xpert Ultra (no studies identified using Xpert Ultra); role: screening test
Threshold for index tests: an automated result is provided












































































































































































































Studies: cross-sectional and cohort studies




Prevalence 0.5% Prevalence 1% Prevalence 2%
Certainty of the evi-
dence (GRADE)
True positives 4 to 5 8 to 10 16 to 20Sensitivity 81%
and 100%
20 (2)
False negatives 0 to 1 0 to 2 0 to 4
⨁◯◯◯a,b,c
Very low





False positives 0 to 60 0 to 59 0 to 59
⨁⨁⨁◯d,e
Moderate
Prevalence estimates were suggested by the WHO Global TB Programme. The prevalence of rifampicin resistance in the studies was 7.3% and 16.7%.
Explanations
aThere were only two studies included in this analysis, conducted in sub-Saharan Africa. The prevalence of rifampicin resistance in the studies was higher than those presented
in the table. The applicability to other settings comes with some uncertainty. We downgraded one level for indirectness.
bThere was a wide range of sensitivities of Xpert MTB/RIF for detection of rifampicin resistance between the two included studies: 81% and 100%. We downgraded one level for
inconsistency.
cThere were few participants contributing to this analysis. We already downgraded one level for inconsistency. We downgraded one level for imprecision.
dOf the three included studies, two were conducted in southern Africa, one in Malaysia. Applicability to other settings comes with some uncertainty. We downgraded one level
for indirectness.
eThe specificities were 94%, 97%, and 100%. One explanation for the lower specificity of 94% is a problem identified with the Xpert MTB/RIF assay, which was modified to improve
specificity aLer publication of this study. We did not downgrade for imprecision.
GRADE certainty of the evidence.
High: we are very confident that the true eJect lies close to that of the estimate of the eJect.
Moderate: we are moderately confident in the eJect estimate: the true eJect is likely to be close to the estimate of the eJect, but there is a possibility that it is substantially
diJerent.
Low: our confidence in the eJect estimate is limited: the true eJect may be substantially diJerent from the estimate of the eJect.
Very low: we have very little confidence in the eJect estimate: the true eJect is likely to be substantially diJerent from the estimate of eJect.
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B A C K G R O U N D
Tuberculosis is the world’s leading cause of infectious disease-
related death and is one of the top 10 causes of death worldwide.
In 2019, an estimated 10 million people developed tuberculosis
disease (WHO Global TB Report 2020).
Among all tuberculosis cases, about 8% were in people living
with HIV (WHO Global TB Report 2020). The risk of developing
tuberculosis is much higher in people living with HIV, estimated
to be 20 to 37 times higher in HIV-positive individuals than in
HIV-negative individuals (Getahun 2010). Signs and symptoms
of tuberculosis in people living with HIV vary, which makes
it challenging to determine when to consider a diagnosis of
tuberculosis - tuberculosis is the leading cause of hospitalisation
and death in people with HIV worldwide (Ford 2016). In addition,
there were around 500,000 new cases of rifampicin-resistant
tuberculosis, of which 78% had multidrug-resistant tuberculosis
(tuberculosis that is resistant to both rifampicin and isoniazid, the
two most essential anti-tuberculosis drugs) (WHO Global TB Report
2020). When tuberculosis is detected early and is eJectively treated,
the disease is largely curable. Ending the tuberculosis epidemic
by 2030 is among the health-related targets described in United
Nations Sustainable Development Goal 3 (WHO END TB 2015).
The United Nations Sustainable Development Goals represent a
collective plan to end poverty, decrease inequality, and protect the
planet from degradation by 2030 (UN Sustainable Development
Goals 2030).
The World Health Organization (WHO) recommends the use of
specific rapid molecular tests, including Xpert MTB/RIF or Xpert
Ultra, the newest version of the assay, as the initial diagnostic tests
for the detection of tuberculosis and rifampicin resistance in people
with signs and symptoms of tuberculosis (WHO Consolidated
Guidelines (Module 3) 2020). However, the WHO estimates that
nearly one-third of all active tuberculosis cases go undiagnosed
and unreported (WHO Global TB Report 2020). In an eJort to close
this diagnostic gap, the WHO is seeking evidence to recommend
case-finding approaches and strategies to improve tuberculosis
case detection of the 'missing millions'. In particular, the WHO
is interested in case-finding approaches in high-risk groups and
settings, such as people living with HIV, people with diabetes
mellitus, and people residing in prisons. Stated another way, the
WHO is interested in the best ways to find the so-called ‘missing
millions’.
Tuberculosis screening is a term that has been used diJerently
in the literature depending on the context. We use tuberculosis
screening as defined by the WHO: the "systematic identification of
people with suspected active TB [tuberculosis], in a predetermined
target group, using tests, examinations or other procedures that
can be applied rapidly." Further, we define intensified case-finding
as tuberculosis screening activities set in health facilities, and
active case-finding as tuberculosis screening activities set in
the community, including household-based or residence-based
screening activities (WHO Systematic screening 2013). The End-
TB strategy emphasizes early diagnosis of tuberculosis, including
universal drug susceptibility testing, and systematic screening of
contacts and high-risk groups (WHO Global TB Report 2020).
Current screening approaches for active tuberculosis typically
recommend initial screening of people living with HIV for four
cardinal signs and symptoms of tuberculosis: cough, fever, weight
loss, and night sweats, or people who do not have HIV, the single
symptom of prolonged cough. People with a positive symptom
screen then may go on to receive additional screening with a
chest X-ray and diagnostic testing using sputum Xpert MTB/RIF or
Xpert Ultra as recommended. Concerning people living with HIV,
a recent systematic review found that the four-symptom screen
had lower sensitivity and specificity for active tuberculosis in HIV-
positive people on antiretroviral therapy (ART) than in HIV-positive
people not taking ART (Hamada 2018). Compared to Xpert MTB/
RIF, Xpert Ultra has shown increased sensitivity for tuberculosis in
HIV-positive people (Dorman 2018). WHO Tuberculosis Standard 8
states, "For persons living with HIV, the Xpert MTB/RIF Ultra assay
should be used as an initial diagnostic test" (WHO Compendium
of WHO guidelines 2018). Recent population surveys using chest
radiography, irrespective of symptoms, as the initial screen for
tuberculosis (followed by diagnostic testing) have identified a
substantial burden of subclinical tuberculosis in people with and
without HIV, supporting a need for new approaches to screen and
identify active tuberculosis using more sensitive tools (Frascella
2020; Gunasekera 2020).
Several Cochrane Reviews have been published or are in process to
assess the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for
diJerent target conditions and in various populations. Of relevance
to the current review, recent Cochrane Reviews found Xpert MTB/
RIF and Xpert Ultra to be highly sensitive and specific for pulmonary
tuberculosis and rifampicin resistance in adults with signs and
symptoms of tuberculosis; see Index test(s) (Horne 2019; Zifodya
2021). The current review determined the accuracy of Xpert MTB/
RIF and Xpert Ultra for tuberculosis and rifampicin resistance in
adults, irrespective of signs and symptoms of tuberculosis, that
is, when used as a screening test. Screening "irrespective of signs
or symptoms" refers to screening of people who have not been
assessed for the presence of tuberculosis symptoms (e.g. cough).
This can include both asymptomatic (people without symptoms of
tuberculosis) and people with symptoms of tuberculosis.
Target condition being diagnosed
Tuberculosis is caused by the bacterium Mycobacterium
tuberculosis (M tuberculosis) and is spread from person to person
through the air. Tuberculosis most commonly aJects the lungs
(pulmonary tuberculosis), but may aJect any organ or tissue
outside of the lungs (extrapulmonary tuberculosis). Signs and
symptoms of pulmonary tuberculosis include cough, fever, chills,
night sweats, weight loss, haemoptysis (coughing up blood),
and fatigue. Signs and symptoms of extrapulmonary tuberculosis
depend on the site of disease. Tuberculosis treatment regimens
must contain multiple drugs, to which the organisms are sensitive,
to cure tuberculosis and avoid selection for drug resistance.
In 2019, there were approximately half a million new cases of
rifampicin-resistant tuberculosis, of which 78% were multidrug-
resistant (MDR-TB) (WHO Global TB Report 2020), The treatment
of MDR-TB is complex, historically requiring two years or more
of therapy, although the WHO conditionally recommended a
regimen of nine to 12 months in 2016 (WHO Guidelines 2016).
The drugs used to treat MDR-TB are less potent and more toxic
than the drugs used to treat drug-susceptible tuberculosis. WHO
guidance states that "All patients with MDR-TB or rifampicin-
resistant tuberculosis, including those with additional resistance
to fluoroquinolones, stand to benefit from eJective all-oral
treatment regimens, either shorter or longer, implemented under
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
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programmatic conditions" (WHO Consolidated Guidelines (Module
4) 2020).
Index test(s)
Xpert MTB/RIF is an automated polymerase chain reaction (PCR)
test (molecular test) using the GeneXpert platform (Cepheid
2019). Xpert MTB/RIF is a single test that can detect both M
tuberculosis complex and rifampicin resistance within two hours
aLer starting the test, with minimal hands-on technical time.
Unlike conventional nucleic acid amplification tests, (NAATs), Xpert
MTB/RIF integrates sample processing and PCR amplification and
detection into a single cartridge. Following sample loading, all
steps in the assay are completely automated and self-contained.
In addition, the assay’s sample reagent, used to liquefy sputum,
has potent tuberculocidal (the ability to kill tuberculosis bacteria)
properties and so largely eliminates biosafety concerns during
the test procedure (Banada 2010). Xpert MTB/RIF requires an
uninterrupted and stable electrical power supply, temperature
control, and yearly calibration of the cartridge modules (Global
Laboratory Initiative 2019).
Since Xpert MTB/RIF was released, there have been four
generations of the test (G1, G2, G3, and G4), involving diJerent
soLware and cartridge combinations. G4 contains modifications
that improved determination of rifampicin resistance detection as
previous Xpert MTB/RIF versions had found that some rifampicin
susceptibility results were falsely resistant. Our previous review
identified considerable overlap of the accuracy estimates for
Xpert MTB/RIF across generations of the test, suggesting that
the diJerence in test generations was unlikely to contribute
meaningfully to heterogeneity in accuracy estimates (Steingart
2014). In order to improve on Xpert MTB/RIF sensitivity, Cepheid
developed Xpert MTB/RIF Ultra (hereaLer referred to as Xpert Ultra),
a re-engineered assay that uses a newly developed cartridge but
may be run on the same device aLer a soLware upgrade. Xpert
Ultra incorporates two diJerent multi-copy amplification targets
and a larger DNA reaction chamber than Xpert MTB/RIF (WHO Xpert
Ultra 2017). A laboratory study reported that the limit of detection
using Xpert Ultra improved to 15.6 CFU/mL of sputum compared to
112.6 CFU/mL for Xpert MTB/RIF (Chakravorty 2017). Of note, Xpert
Ultra has added a new result category, ‘trace call', that corresponds
to the lowest bacillary burden for M tuberculosis detection (WHO
Xpert Ultra 2017). Although no result for rifampicin resistance will
be available for people with trace results, a trace-positive result
is suJicient to initiate anti-tuberculosis therapy in children or
HIV-positive people, according to the WHO report. Xpert Ultra is
available for clinical use and several countries have moved from
using Xpert MTB/RIF to using Xpert Ultra instead. In this Cochrane
Review, we included studies that used any generation of the index
tests.
Regarding the accuracy of Xpert MTB/RIF and Xpert Ultra for
diagnosis of pulmonary tuberculosis in people with signs and
symptoms, a recent Cochrane Review found pooled sensitivity and
specificity (95% credible interval) against culture were 90.9% (86.2
to 94.7) and 95.6% (93.0 to 97.4) for Xpert Ultra (7 studies, 2834
participants; high-certainty evidence) and 84.7% (78.6 to 89.9) and
98.4% (97.0 to 99.3) for Xpert MTB/RIF (7 studies, 2835 participants;
high-certainty evidence), For detection of rifampicin resistance,
pooled sensitivity and specificity were 94.9% (88.9 to 97.9) and
99.1% (97.7 to 99.8) for Xpert Ultra (5 studies, 921 participants; high-
certainty evidence) versus 95.3% (90.0 to 98.1) and 98.8% (97.2 to
99.6) for Xpert MTB/RIF (5 studies, 930 participants; high-certainty
evidence) (Zifodya 2021).
Clinical pathway
There are two complementary approaches to detection of active
tuberculosis, Figure 1. The first is the patient-initiated pathway, also
known as passive case finding. The second is the provider-initiated
screening pathway, which represents the analytic framework for
this review (WHO Systematic screening 2015). The index test, either
Xpert MTB/RIF or Xpert Ultra, would be performed as the only
test for pulmonary tuberculosis and rifampicin resistance in adults,
irrespective of signs or symptoms of pulmonary tuberculosis, in
high-risk groups and in primary health facilities or community
settings.
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Figure 1.   There are two complementary approaches to detection of active tuberculosis. The first is the patient-
initiated pathway, also known as passive case finding. The second is the provider-initiated screening pathway (WHO
Systematic screening 2015), which represents the analytic framework for this review. In the latter pathway, the
index test would be applied as the only test, to adults, irrespective of signs and symptoms of tuberculosis, in high-
risk groups and in primary health facilities or community settings.
 
The purpose of the index tests is screening.
The role of the index tests is replacement for usual practice. This
may include replacement for the WHO four-question symptom
screen.
The downstream consequences of screening include the following.
• True-positive (TP): patients would benefit from rapid diagnosis
and initiation of appropriate treatment.
• True-negative (TN): patients would be spared unnecessary
treatment and would benefit from reassurance, pursuit of an
alternative diagnosis if they have symptoms, and determination
of eligibility for tuberculosis preventive therapy if indicated.
• False-positive (FP): patients would probably experience anxiety
and morbidity caused by additional testing, unnecessary
treatment, and possible adverse events; possible stigma
associated with a tuberculosis or MDR-TB diagnosis; and the
chance that a false-positive result may halt further diagnostic
evaluation of the true underlying condition.
• False-negative (FN): patients would experience an increased
risk of morbidity and mortality, and delayed or inappropriate
treatment initiation; there would be risk of ongoing tuberculosis
transmission.
Alternative test(s)
Alternative screening tests for tuberculosis include no screening
(or passive case-finding), and one or more of symptom screening
(such as the WHO four-question symptom screen) and chest X-ray,
which must be further confirmed with a diagnostic test. Other tools
that may be useful in screening include urine lipoarabinomannan
(LAM) testing and smear microscopy, which require additional
definitive drug resistance testing even if used as simultaneous
screening and diagnostic tests. We have previously described
selected alternative tests for detection of pulmonary tuberculosis
and rifampicin resistance (Horne 2019; Lewinsohn 2017; Unitaid
2017). A Special Collection curated by Cochrane contributors
includes Cochrane Reviews from Cochrane Infectious Diseases
and other systematic reviews from other international teams. The
Special Collection describes key WHO guidelines on tuberculosis
diagnostics, and their underpinning systematic reviews (Cochrane
Special Collection 2020). Below we review screening tools and
highlight several recent developments in tuberculosis diagnostics.
Numerous symptoms, singly and in combination, have been
proposed to screen for tuberculosis in diJerent settings. A
healthcare or community worker asks the person being screened
if they are experiencing any of the selected symptoms, and those
who report symptoms according to local criteria go on to receive
additional testing such as chest X-ray or diagnostic testing. The
most commonly assessed symptoms are cough (varying duration),
fever, weight loss, drenching night sweats, loss of appetite,
haemoptysis, and fatigue. Single symptoms have modest to low
sensitivity; defining a positive screen as any one or more of
multiple symptoms improves sensitivity but reduces specificity,
consequently increasing the number of diagnostic confirmatory
tests. Accuracy of symptom screening varies with the HIV status of
the people screened. One study found that any one of cough of
any duration, fever of any duration, or night sweats lasting three
or more weeks was the most sensitive combination of symptoms
for identification of tuberculosis in people living with HIV (93%
sensitivity, 36% specificity; Cain 2010). In mixed HIV-positive and
HIV-negative populations, a single symptom of cough of greater
than two weeks' duration identified 35% (95% confidence interval
(CI) 24 to 46) of adults with culture-positive pulmonary tuberculosis
in one systematic review and modelling analysis; any one of a list of
tuberculosis symptoms had 70% sensitivity and 61% specificity for
pulmonary tuberculosis in low-HIV-prevalence settings (van't Hoog
2013).
Chest X-ray can involve posterior-anterior, anterior-posterior, or
lateral recording, or a combination of two or all of these. Major
types of chest X-ray include conventional chest X-ray (producing 36
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cm x 43 cm film), digital radiography, and computed radiography.
Chest X-ray findings including hilar lymphadenopathy, cavitary
lesions, and evidence of granulomas can all suggest pulmonary
tuberculosis, but are also nonspecific and must be confirmed
with additional testing. Accurate interpretation of pulmonary
tuberculosis findings on chest X-ray are dependent on the ability
of the individual interpreting the chest X-ray, and wide inter-
observer variation has been reported (Zellweger 2006). Computer-
aided interpretation of chest X-ray for pulmonary tuberculosis is a
promising new technology, especially for resource-limited settings
where expertise in chest X-ray interpretation is limited (Harris 2019).
Smear microscopy is the examination of smears for acid-
fast bacilli (tuberculosis bacteria) under a microscope. The
examination may be performed by light microscopy (Ziehl-
Neelsen), fluorescence microscopy, or light-emitting diode (LED)
fluorescence microscopy. Microscopy cannot distinguish between
drug-susceptible tuberculosis and drug-resistant tuberculosis. The
WHO recommends that microscopy, as the initial diagnostic test,
should be replaced with WHO-recommended rapid tests that
can simultaneously detect tuberculosis and tuberculosis drug
resistance (WHO Consolidated Guidelines (Module 3) 2020).
Nucleic acid amplification tests (NAATs) are molecular systems that
can detect small quantities of genetic material (DNA or RNA) from
micro-organisms, such as M tuberculosis. The key advantage of
NAATs is that they are rapid diagnostic tests, potentially providing
results in a few hours. Several new commercial NAATs are in
the diagnostic pipeline or have recently come to market (e.g.
Truenat MTB, Truenat MTBplus, and Truenat MTB-RIF Dx, Molbio
Diagnostics, India). Truenat MTB and Truenat MTB Plus assays
show comparable accuracy with Xpert MTB/RIF and Xpert Ultra for
detection of tuberculosis, and for sequential detection of rifampicin
resistance (Truenat MTB-Rif Dx) (WHO Consolidated Guidelines
(Module 3) 2020).
Alere Determine TB LAM Ag (AlereLAM, Alere Inc, Waltham, USA) is a
commercially available, point-of-care test for tuberculosis disease
(pulmonary and extrapulmonary tuberculosis). The test detects
lipoarabinomannan (LAM), a component of the bacterial cell wall,
which is present in the urine of some people with tuberculosis.
AlereLAM is performed by placing urine on one end of a test strip,
with results appearing as a band on the strip if tuberculosis is
present. The test is simple, requires no special equipment, and
shows results in 25 minutes (Bjerrum 2019). In two randomized
trials, the use of Alere LAM in HIV-positive inpatients has been
shown to reduce mortality (Gupta-Wright 2018; Peter 2016). Based
on evidence from the randomized trials and a Cochrane Review
(Bjerrum 2019), the WHO recommends that AlereLAM should be
used to assist in the diagnosis of active tuberculosis in HIV-positive
adults, adolescents and children. The full recommendations, which
diJer for inpatients and outpatients, are described here: (WHO
Consolidated Guidelines (Module 3) 2020).
Fujifilm SILVAMP TB LAM (FujiLAM, co-developed by Foundation
for Innovative New Diagnostics (FIND), Geneva, Switzerland and
Fujifilm, Tokyo, Japan) is a new, urine-based, point-of-care test for
tuberculosis diagnosis in people living with HIV. In an individual
participant data meta-analysis that included five cohorts of people
living with HIV, FujiLAM was found to have superior sensitivity,
70.7% (95% CI 59.0% to 80.8%), compared to AlereLAM sensitivity
of 42.3% (31.7% to 51.8%), against a microbiological reference
standard; FujiLAM had lower specificity, 90.9% (87.2% to 93.7%),
compared to AlereLAM specificity of 95.3% (92.2% to 97.7%) (Broger
2020).
Alternative molecular methods for drug susceptibility testing
include the commercial line probe assays, GenoType MTBDRplus
assay (MTBDRplus, Hain LifeScience, Nehren, Germany), and the
Nipro NTM+MDRTB detection kit 2 (Nipro, Tokyo, Japan), which
detect the presence of mutations associated with drug resistance
to isoniazid and rifampicin (WHO Consolidated Guidelines (Module
3) 2020). Advantages of line probe assays are that they can provide
a result for detection of tuberculosis and drug resistance in one to
two days. Drawbacks are that line probe assays are expensive and
need to be used in intermediate and central laboratories (Unitaid
2017).
Rationale
Since 2010, the WHO has recommended the use of Xpert MTB/
RIF as the preferred initial diagnostic test for people thought
to have MDR-TB or HIV-associated tuberculosis (WHO 2011). In
2013, the WHO expanded the recommendations, stating that Xpert
MTB/RIF may be used rather than conventional microscopy and
culture as the initial diagnostic test in all adults suspected of
having tuberculosis (conditional recommendation acknowledging
resource implications, high-quality evidence; WHO Xpert MTB/RIF
2013). In addition, the WHO recommended that following an Xpert
MTB/RIF test that demonstrates rifampicin resistance, subsequent
drug susceptibility testing (e.g. using a line probe assay for second-
line drugs) remains essential to detect resistance to drugs other
than rifampicin (WHO Xpert MTB/RIF 2013). In 2017, based on a
non-inferiority analysis of Xpert Ultra compared with Xpert MTB/RIF
(Dorman 2018), the WHO stated that recommendations on the use
of Xpert MTB/RIF also apply to the use of Xpert Ultra as the initial
diagnostic test for all adults and children with signs and symptoms
of tuberculosis (WHO Consolidated Guidelines (Module 3) 2020).
Given the demonstrated success of rapid molecular tests for
diagnosing tuberculosis, we were interested whether a single
test, Xpert MTB/RIF or Xpert Ultra, can be useful as a screening
test to identify people with active pulmonary tuberculosis in
high-risk groups and the in the general population. The settings
were community settings or healthcare settings attended for
reasons unrelated to tuberculosis. This is a diJerent approach
than diagnosing active tuberculosis in people with signs and
symptoms of tuberculosis who seek care in health facilities. We
performed this Cochrane Review to inform an updated WHO
policy on tuberculosis screening, 2020 Revision of the Guidelines
for Systematic Screening for Active Tuberculosis: Updated and
Consolidated Recommendations and Implementation Guidance
(WHO Rapid Communication 2020). The 2020 WHO guidelines
also include Cochrane and non-Cochrane systematic reviews
on symptom screening, chest radiography, and other tests and
strategies for screening for tuberculosis in adults and children.
O B J E C T I V E S
To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra for
screening of pulmonary tuberculosis in adults in the following high-
risk groups.
• People living with HIV.
• Household contacts of people with tuberculosis.
• People residing in prisons.
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• Miners.
• Patients residing in high tuberculosis burden settings attending
primary health facilities.
• People experiencing homelessness.
• People with diabetes mellitus.
• People who abuse alcohol.
• People who smoke.
• Healthcare workers.
To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra
for screening for tuberculosis in adults, irrespective of signs or
symptoms of pulmonary tuberculosis in the general population (i.e.
low-risk population).
To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra for
the detection of rifampicin resistance in the high-risk groups and
settings described above and in the general population.
Secondary objectives
To compare the accuracy of Xpert MTB/RIF and Xpert Ultra in the
above high-risk groups and settings and in the general population.
To investigate potential sources of heterogeneity in accuracy
estimates, including the percentage of participants with
tuberculosis symptoms, tuberculosis burden, and tuberculosis/HIV
burden (tuberculosis detection), and MDR-TB burden (rifampicin
resistance detection).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included cross-sectional studies and cohort studies that
estimated the accuracy of one or both index tests for both
pulmonary tuberculosis and rifampicin resistance or pulmonary
tuberculosis alone. We used abstracts to identify published studies
and included the full publications when they met our inclusion
criteria. We only included studies that reported data comparing the
index test(s) to an acceptable reference standard from which we
could extract true positive (TP), true negative (TN), false positive
(FP), and false negative (FN) values. The index tests could be
assessed alone or together with other tests. We included studies
designed to find people with active tuberculosis in community
settings. We included abstracts with suJicient data to populate a
2x2 contingency table.
We excluded case reports and studies with a case-control design,
the latter because these types of studies are prone to bias, in
particular, studies enrolling participants with severe disease and
healthy participants without disease. We excluded drug resistance
surveys.
Participants
Adults, defined as 15 years of age and older, irrespective of signs or
symptoms of pulmonary tuberculosis in high-risk groups and in the
general population. High-risk groups included the following:
• People living with HIV.
• Household contacts of people with tuberculosis.
• People residing in prisons.
• Miners.
• Patients attending primary health facilities.
• Homeless people.
• People with diabetes mellitus.
• People who abuse alcohol.
• Smokers.
• Healthcare workers.
The settings of interest were primary healthcare facilities and other
community settings.
We excluded studies that selected participants for enrolment based
on the results of prior tuberculosis testing, such as symptom
screening or chest radiography.
Index tests
The index test were sputum Xpert MTB/RIF and sputum Xpert
Ultra. Test results are automatically generated (i.e. there is a single
threshold), and the user is provided with a printable test result as
follows.
Xpert MTB/RIF (Cepheid 2019)
• MTB (M tuberculosis) DETECTED; RIF (rifampicin) Resistance
DETECTED
• MTB DETECTED; RIF Resistance NOT DETECTED
• MTB detected; RIF Resistance INDETERMINATE
• MTB NOT DETECTED.
• INVALID (the presence or absence of MTB cannot be determined)
• ERROR (the presence or absence of MTB cannot be determined)
• NO RESULT (the presence or absence of MTB cannot be
determined
Xpert Ultra (Cepheid 2018)
• MTB (M tuberculosis) DETECTED HIGH; RIF (rifampicin)
Resistance DETECTED
• MTB DETECTED MEDIUM; RIF Resistance DETECTED
• MTB DETECTED LOW; RIF Resistance DETECTED
• MTB DETECTED VERY LOW; RIF Resistance DETECTED
• MTB DETECTED HIGH; RIF Resistance NOT DETECTED
• MTB DETECTED MEDIUM; RIF Resistance NOT DETECTED
• MTB DETECTED LOW; RIF Resistance NOT DETECTED
• MTB DETECTED VERY LOW; RIF Resistance NOT DETECTED
• MTB DETECTED HIGH; RIF Resistance INDETERMINATE
• MTB DETECTED MEDIUM; RIF Resistance INDETERMINATE
• MTB DETECTED LOW; RIF Resistance INDETERMINATE
• MTB DETECTED VERY LOW; RIF Resistance INDETERMINATE
• MTB Trace DETECTED; RIF Resistance INDETERMINATE
• INVALID (the presence or absence of MTB cannot be determined)
• ERROR (the presence or absence of MTB cannot be determined)
• NO RESULT (the presence or absence of MTB cannot be
determined)
Xpert Ultra incorporates a semi-quantitative classification for
results. MTB Trace DETECTED corresponds to the lowest bacterial
burden for detection of M tuberculosis (Chakravorty 2017). We
considered a trace result to mean MTB (M tuberculosis) DETECTED.
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However, no rifampicin-resistance results were available for
participants with trace results because for trace results, rifampicin
resistance is always reported as INDETERMINATE (Cepheid 2018).
Target conditions
The target conditions were active pulmonary tuberculosis and
rifampicin resistance.
Reference standards
For tuberculosis, the reference standards were solid culture or
automated liquid culture.
For rifampicin resistance, the reference standards were culture-
based drug susceptibility testing (DST) and line probe assays (WHO
LPA 2016). Acceptable methods for DST included the proportion
method, performed on solid media, such as Lowenstein-Jensen,
and use of a commercial liquid culture system, such as
Mycobacteria Growth Indicator Tube (MGIT) 960 automated
mycobacterial detection system (BD, USA).
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, and
ongoing).
Electronic searches
We searched the following databases on 19 March 2020, without
language restriction, using the search terms and strategy described
in Appendix 1.
• Cochrane Infectious Diseases Specialized Register.
• MEDLINE (Pubmed, from 1966).
• Embase (OVID, from 1947).
• Science Citation Index - Expanded (from 1900), Conference
Proceedings Citation Index - Science (CPCI-S, from 1990), Social
Science Citation Index (from 1900), Conference Proceedings
Citation Index- Social Science & Humanities(from 1990), all from
the Web of Science.
• Scopus (Elsevier, from 1970).
• Latin American Caribbean Health Sciences Literature (LILACS;
BIREME, https://lilacs.bvsalud.org/en/ from 1982).
We also searched ClinicalTrials.gov, the WHO International Clinical
Trials Registry Platform (ICTRP; www.who.int/trialsearch), and
the International Standard Randomized Controlled Trials Number
(ISRCTN) registry (www.isrctn.com/), for trials in progress, and
ProQuest Dissertations & Theses A&I (from 1990) for dissertations.
Searching other resources
We reviewed reference lists of included articles, related Cochrane
Reviews (Horne 2019) and any relevant review articles identified
through the above methods. We also contacted researchers at
the Foundation for Innovative New Diagnostics (FIND), the WHO
Global TB Programme, and other experts in the field of tuberculosis
diagnostics for information on ongoing and unpublished studies.
Data collection and analysis
Selection of studies
We used Covidence to manage the selection of studies (Covidence).
Two review authors independently and in parallel scrutinized
titles and abstracts identified from literature searching to identify
potentially eligible studies. We retrieved the article of any
citation, identified by any review author, for full-text review. Two
review authors independently and in parallel assessed articles
for inclusion using the predefined selection criteria. We resolved
any discrepancies by discussion or with a third review author. We
recorded all studies excluded aLer full-text assessment, along with
our reasons for their exclusion in the Characteristics of excluded
studies table, and illustrated the study selection process in a
PRISMA diagram (Moher 2009).
Data extraction and management
We extracted data on the following characteristics.
• Author, publication year, study design, country where study was
located, clinical setting.
• Population characteristics: age, sex, AFB smear status, HIV
status.
• Index test(s), Xpert MTB/RIF or Xpert Ultra.
• Reference standard.
• Quality Assessment of Studies of Diagnostic Accuracy - Revised
(QUADAS-2) items (Whiting 2011).
• Number of TP, FP, FN, and TN (i.e. true positives, false positives,
false negatives, and true negatives) and trace results, with
respect to culture.
• Number of uninterpretable results for detection of pulmonary
tuberculosis.
• Number of indeterminate results for detection of rifampicin
resistance.
We classified country income status as either low- and middle-
income or high-income, according to the World Bank List of
Economies (World Bank 2020). In addition, we classified ‘country'
as being high burden or not high burden for tuberculosis, TB/HIV,
or MDR-TB, according to the classification by the WHO (WHO Global
TB Report 2019).
We followed Cochrane policy, which states that "authors of primary
studies will not extract data from their own study or studies.
Instead, another author will extract these data, and check the
interpretation against the study report and any available study
registration details or protocol".
Assessment of methodological quality
We used the QUADAS-2 tool, tailored to this review, to assess
the quality of the included studies (Whiting 2011; Appendix 2).
QUADAS-2 consists of four domains: patient selection, index test,
reference standard, and flow and timing. We assessed all domains
for risk of bias and the first three domains for concerns regarding
applicability. We presented the results of this quality assessment in
text, tables, and graphs.
Statistical analysis and data synthesis
We performed descriptive analyses for the results of the included
studies using Stata 15 (Stata). We determined sensitivity and
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specificity estimates and 95% confidence intervals (CIs) for
individual studies and generated forest plots using Review Manager
5 (Review Manager 2020).
When possible, we carried out meta-analyses to estimate the
pooled sensitivity and specificity of the index tests separately
for tuberculosis detection and rifampicin resistance detection. We
determined the pooled accuracy estimates using an adaptation of
the bivariate random-eJects model of Reitsma 2005, which uses the
exact binomial likelihood for the observed proportions (Chu 2006).
The bivariate random-eJects approach allows us to calculate the
pooled estimates of sensitivity and specificity while accounting for:
1. variation in sensitivity and specificity estimates within
individual studies;
2. correlation between sensitivity and specificity across studies;
and
3. variation in sensitivity and specificity between studies.
In addition, we determined positive and negative predictive values
at pretest probabilities (0.5% and 5%) suggested by the WHO.
For analysis of Xpert MTB/RIF or Xpert Ultra accuracy for detection
of rifampicin resistance, we included participants who:
1. were culture-positive;
2. had a valid phenotypic drug susceptibility test (DST) or line
probe assay (LPA) result;
3. were Xpert MTB/RIF or Xpert Ultra tuberculosis-positive; and
4. had a valid Xpert MTB/RIF or Xpert Ultra result for rifampicin
resistance, detected or not detected (susceptible).
Sensitivity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance
detected/phenotypic DST or LPA rifampicin-resistant
Specificity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance not
detected/phenotypic DST or LPA rifampicin-susceptible
We estimated all models using a Bayesian approach, with low-
information prior distributions, using OpenBUGS soLware (Version
3.2.3; Lunn 2009), along with R (Version 3.3.2; R Core Team 2019).
Under the Bayesian approach, all unknown parameters must be
provided a prior distribution that defines the range of possible
values of the parameter and the likelihood of each of those values
based on information external to the data. In order to let the
observed data determine the final results, we chose to use low-
information prior distributions over the pooled sensitivity and
specificity parameters and their between-study standard deviation
parameters.
Meta-analysis models can be sensitive to the choice of prior
distributions over between-study standard deviation parameters.
We therefore carried out sensitivity analyses and considered
alternative prior distributions that are less informative, allowing
a wider range of possible values. We included information from
the prior distribution in combination with the observed data in
accordance with Bayes' theorem to obtain a posterior distribution
for each unknown parameter.
Using a sample from the posterior distribution, we can obtain
various descriptive statistics of interest. We estimated the median
pooled sensitivity and specificity and their 95% credible intervals
(CrIs). The median or the 50% quantile is the value below which
lies 50% of the posterior sample. We reported the median because
the posterior distributions of some parameters may be skewed
and the median would be considered a better point estimate
of the unknown parameter than the mean in such cases. The
95% CrI is the Bayesian equivalent of the classical (frequentist)
95% CI. (We indicated 95% CI for individual study estimates and
95% CrI for pooled study estimates, as appropriate.) The 95% CrI
may be interpreted as an interval that has a 95% probability of
capturing the true value of the unknown parameter, given the
observed data and the prior information. We generated bivariate
plots of the credible and prediction regions in the receiver operating
characteristic (ROC) space using R (version 3.3.2; R Core Team 2019).
We found only one study that compared the accuracy of Xpert MTB/
RIF and Xpert Ultra in a single high-risk group and setting, thus we
analysed the accuracy estimates descriptively in text, tables, and
forest plots.
Approach to uninterpretable index test results
The index tests report an uninterpretable test result for unexpected
results with any of the internal control measures of the assay.
In previous reviews, we found very few uninterpretable results
reported, as was the case here, and chose to exclude them from the
bivariate meta-analyses (Horne 2019).
Investigations of heterogeneity
We visually inspected forest plots and the summary receiver
operating characteristic (SROC) plots for heterogeneity. We set
out to investigate a number of potential sources of heterogeneity,
described below using subgroup analyses; however, our ability to
investigate these sources was limited by the available data. We
added percentage of participants with tuberculosis symptoms as
a continuous covariate on forest plots and visually inspected the
plots. We intended to perform subgroup analyses among studies
conducted in high versus not high tuberculosis burden countries,
and similarly for high TB/HIV burden and high MDR-TB burden
versus not high-burden countries. However, most studies were
conducted in high-burden countries (DiJerences between protocol
and review).
Sensitivity analyses
We intended to perform sensitivity analyses by limiting inclusion in
the meta-analyses according to the following criteria:
• studies that explicitly represented the use of the index tests for
the screening of individuals irrespective of signs and symptoms
of tuberculosis;
• studies that used liquid culture as the reference standard;
• studies where a consecutive or random sample of participants
were enrolled. We planned to exclude studies where we
answered no or unclear to the QUADAS-2 patient selection
signalling question: "Could the selection of patients have
introduced bias?"
However, we did not perform any sensitivity analyses because
all studies met these criteria (DiJerences between protocol and
review).
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Assessment of reporting bias
We did not formally assess reporting bias using funnel plots or
regression tests as these have not been reported as helpful for
diagnostic test accuracy studies (Macaskill 2010).
Summary of findings and assessment of the certainty of the
evidence
We assessed the certainty of the evidence using the GRADE
approach (Balshem 2011; Schünemann 2008; Schünemann 2016),
and GRADEpro GDT 2020 soLware. In the context of a systematic
review, ratings of the certainty of the evidence reflect the extent
of our confidence that the estimates of eJect (including test
accuracy and associations) are correct. As recommended, we rated
the certainty of the evidence as either high (not downgraded),
moderate (downgraded by one level), low (downgraded by two
levels), or very low (downgraded by more than two levels) for five
domains: risk of bias, indirectness, inconsistency, imprecision, and
publication bias.
For each outcome, we considered the certainty of the evidence
to begin as high when high-quality observational studies (cross-
sectional or cohort studies) enrolled participants with diagnostic
uncertainty. If we had a reason for downgrading, we used our
judgement to classify the reason as serious (downgraded by one
level) or very serious (downgraded by two levels). We summarized
this information in the ‘Summary of findings' tables.
As recommended, we applied GRADE in the following ways
(Schünemann 2020a; Schünemann 2020b).
• Risk of bias: we used QUADAS-2 to assess risk of bias.
• Indirectness: we assessed indirectness in relation to the
population (including disease spectrum), setting, interventions,
and outcomes (accuracy measures). For example, we noted
whether the population was the same in the studies compared
to the question asked. We also used prevalence as a guide to
whether there was indirectness in the population.
• Inconsistency: GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity
estimates. We carried out prespecified analyses and
downgraded only when we could not explain inconsistency in
the accuracy estimates.
• Imprecision: we considered a precise estimate to be one that
would allow a clinically meaningful decision. We considered the
width of the CrI and ask ourselves, ‘Would we make a diJerent
decision if the lower or upper boundary of the CrI represented
the truth?’ In addition, we determined projected ranges for true
positives (TP), false negatives (FN), true negatives (TN), and false
positives (FP) for a given prevalence of tuberculosis and make
judgements on imprecision from these calculations.
• Publication bias: we considered the comprehensiveness of the
literature search and outreach to researchers in tuberculosis,
the presence of only studies that produce precise estimates of
high accuracy despite small sample size, and knowledge about
studies that were conducted, but are not published.
R E S U L T S
Results of the search
We identified 1794 records through database searching and one
additional record through other sources. ALer duplicate removal,
we screened a total of 1792 citations by title and abstract for
inclusion. Of these, we assessed 119 full-text publications against
our inclusion criteria and excluded 99 publications. Exclusions were
mainly due to persons not screened irrespective of symptoms (n
= 61), no microbiologic reference standard (n = 14), duplicate data
from another study (n = 7), and data insuJicient for the 2x2 table
(n = 6). Other reasons for exclusion included Xpert MTB/RIF used
on a non-respiratory specimen (n = 3), paediatric population (n =
3), data not disaggregated on persons screened with or regardless
of symptoms (n = 2), not original research (n = 2), and number of
positive tests not reported (n = 1).
Thus we identified 20 publications, which included 21 unique
studies (one publication contributed two distinct cohorts). (Al-
Darraji 2013; Al-Darraji 2016; Balcha 2014; Beyanga 2018; Bjerrum
2016; Dorman 2012; Heidebrecht 2016; Henostroza 2016; Kempker
2019; LaCourse 2016; Lawn 2011; Lawn 2012; Lopez-Varela 2019;
Mollel 2017; Ntinginya 2012; O'Grady 2012; Reeve 2019a; Reeve
2019b; Santos 2020; Tahseen 2018; Yoon 2017). Of the total 21
studies, 18 studies provided data for the detection of pulmonary
tuberculosis using Xpert MTB/RIF and one study provided data
for both Xpert MTB/RIF and Xpert Ultra (Reeve 2019b). Three
studies provided data for detection of rifampicin resistance (Al-
Darraji 2013; Lawn 2011; O'Grady 2012). All included studies used
a cross-sectional study design. We did not identify any studies that
conducted general population-wide screening for tuberculosis (e.g.
national prevalence surveys) that met inclusion criteria for this
review. Figure 2 shows the flow of studies in the review. We recorded
the excluded studies and the reasons for their exclusion in the
Characteristics of excluded studies table.
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Figure 2.   Study flow diagram, PRISMA. *One publication, Reeve 2019, contributed two distinct studies, which were
classified as Reeve 2019a and Reeve 2019b.
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Methodological quality of included studies
Xpert MTB/RIF and Xpert Ultra as screening tests for
pulmonary tuberculosis
Figure 3 and Figure 4 summarize risk of bias and applicability
concerns for studies evaluating Xpert MTB/RIF (n = 20) and Xpert
Ultra (n = 1) as screening tests for pulmonary tuberculosis.
 
Figure 3.   Risk of bias and applicability concerns graph for Xpert MTB/RIF and Xpert Ultra as screening tests for
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Figure 4.   Risk of bias and applicability concerns summary for Xpert MTB/RIF and Xpert Ultra as screening tests for
pulmonary tuberculosis: review authors' judgements about each domain for each included study.
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In the patient selection domain, we considered all studies
to have low risk of bias because the studies enrolled a
consecutive or random sample of eligible adult participants and
avoided inappropriate exclusions. Regarding applicability (Patient
Selection domain), we considered 16 studies (76%) to have low
concern because the study population resembled a population
that was selected for tuberculosis screening in community settings
or primary care centres. We considered two studies (10%) to
have high concern because participants were evaluated exclusively
as inpatients in tertiary care centres (Heidebrecht 2016; O'Grady
2012), and three studies (14%) to have unclear concern, two studies
because they enrolled a small proportion of people younger than
15 years old (Beyanga 2018; Ntinginya 2012), and one study because
2% of the enrolled population had received tuberculosis treatment
for up to two weeks (Balcha 2014).
In the index test domain, we considered all studies to have low risk
of bias because the results of the index tests (Xpert MTB/RIF and
Xpert Ultra) are automatically generated, the user is provided with
printable test results, and the positivity threshold is prespecified.
Regarding applicability (Index Test domain), we considered all
studies to have low concern.
In the reference standard domain, we considered 20 studies
(95%) to have low risk of bias. We considered one study to have
unclear risk of bias because information about blinding was not
reported (Mollel 2017). Regarding applicability (Reference Standard
domain), we considered 20 studies (95%) to have low concern
because these studies performed a test to identify M tuberculosis
species (speciation) and one study to have unclear concern because
information about speciation was not reported (Mollel 2017).
In the flow and timing domain, we considered 18 studies (86%)
to have low risk of bias because all participants were included in
the analysis. We considered three studies to have high risk of bias
because not all enrolled participants were included in the analysis
(Heidebrecht 2016; Ntinginya 2012; Santos 2020).
Xpert MTB/RIF and Xpert Ultra as screening tests for rifampicin
resistance
Figure 5 and Figure 6 show risk of bias and applicability concerns
for studies evaluating Xpert MTB/RIF (n = 3) as screening tests for
rifampicin resistance.
 
Figure 5.   Risk of bias and applicability concerns graph for Xpert MTB/RIF as a screening test for rifampicin
resistance: review authors' judgements about each domain presented as percentages across included studies.
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Figure 6.   Risk of bias and applicability concerns summary for Xpert MTB/RIF as a screening test for rifampicin
resistance: review authors' judgements about each domain for each included study.
 
Regarding risk of bias, for the four domains (patient selection, index
test, reference standard, and flow and timing), we considered all
three studies (100%) to at low risk (Al-Darraji 2013; Lawn 2011;
O'Grady 2012). Regarding applicability, in the Patient Selection
domain, we considered two studies (67%) to have low concern
about applicability (Al-Darraji 2013; Lawn 2011), and one study
to have unclear concern because participants were evaluated
exclusively as inpatients in a tertiary care centre (O'Grady 2012).
Findings
The median study population size of the included studies was 442
(Interquartile range (IQR) 114 to 624). FiLeen studies (75%) were
conducted in high tuberculosis burden and 16 (80%) in high TB/HIV-
burden countries. We presented key characteristics of the included
studies in the Characteristics of included studies table. Twelve
(60%) studies were performed in people living with HIV. Of the total
21 studies, none evaluated the tests for screening in the general
population.
Xpert MTB/RIF and Xpert Ultra as screening tests for
pulmonary tuberculosis
Xpert MTB/RIF as a screening test in people living with HIV,
irrespective of tuberculosis symptoms
Twelve studies evaluated Xpert MTB/RIF as a screening test
for pulmonary tuberculosis in people living with HIV (Al-Darraji
2013; Balcha 2014; Bjerrum 2016; Henostroza 2016; Kempker
2019; LaCourse 2016; Lawn 2012; Lopez-Varela 2019; Mollel
2017; Reeve 2019a; Tahseen 2018; Yoon 2017). Xpert MTB/RIF
sensitivity estimates varied from 43% to 100%. The lowest
sensitivity was reported by LaCourse 2016, a study notable for
enrolling HIV-positive women accessing prevention of mother-to-
child transmission services as part of antenatal care. Specificity
varied less than sensitivity, from 92% to 100%, Figure 7. Xpert MTB/
RIF pooled sensitivity and specificity (95% CrI) were 61.8% (53.6 to
69.9) and 98.8% (98.0 to 99.4), (12 studies, 4775 participants, 602
(12.6%) with tuberculosis), Table 1, Figure 8.
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Figure 7.   Forest plots of Xpert MTB/RIF sensitivity and specificity for pulmonary tuberculosis in people living
with HIV by percentage of tuberculosis symptoms. The individual studies are ordered by decreasing percentage of
participants with tuberculosis symptoms. The squares represent the sensitivity and specificity of one study, the
black line its confidence interval. TP: true-positive; FP: false-positive; FN: false-negative; TN: true-negative.
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Figure 8.   Summary plots of the accuracy of Xpert MTB/RIF as a screening test for pulmonary tuberculosis in (A)
people living with HIV and (B) non-hospitalized people in high-risk groups. Each individual study is represented
by a shaded circle. The size of the circle is proportional to the sample size of the study such that larger studies are
represented by larger circles. The filled circle is the median pooled estimate for sensitivity and specificity. The
solid lines represent the 95% credible region around the summary estimate; the dashed lines represent the 95%




Xpert MTB/RIF as a screening test in people living with HIV, by
percentage of participants with tuberculosis symptoms
In HIV-positive populations where 50% or more had tuberculosis
symptoms, Xpert MTB/RIF pooled sensitivity and specificity (95%
CrI) were 62.9% (53.9 to 72.1) and 98.7% (97.7 to 99.4), (9 studies,
3791 participants, 571 (15.1%) with tuberculosis).
In HIV-positive populations where less than 50% had tuberculosis
symptoms, Xpert MTB/RIF pooled sensitivity and specificity (95%
CrI) were 61.1% (35.5 to 82.3) and 99.1% (97.6 to 99.8), (3 studies,
984 participants, 31 (3.2%) with tuberculosis).
Confidence intervals for sensitivity and specificity estimates in the
two subgroups overlapped, indicating no significant diJerences in
accuracy based on tuberculosis symptoms, Table 1, Figure 7.
Xpert Ultra as a screening test in people living with HIV,
irrespective of tuberculosis symptoms
One study evaluated Xpert Ultra as a screening test for pulmonary
tuberculosis (Reeve 2019b). Xpert Ultra sensitivity and specificity
(95% CI) were 69% (57 to 80) and 98% (97 to 99), Figure 7.
Xpert MTB/RIF as a screening test in household contacts,
irrespective of tuberculosis symptoms
Two studies evaluated Xpert MTB/RIF as a screening test for
pulmonary tuberculosis in household contacts. Xpert MTB/RIF
sensitivity and specificity (95% CI) were 33% (13 to 59) and 98% (97
to 99) (Beyanga 2018) and 100% (48 to 100) and 100% (93 to 100)
(Ntinginya 2012), Figure 9.
 
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
or symptoms (Review)










Cochrane Database of Systematic Reviews
Figure 9.   Forest plots of Xpert MTB/RIF sensitivity and specificity for pulmonary tuberculosis in household contacts,
people in prison, miners, and people admitted to hospital, irrespective of tuberculosis symptoms. The squares
represent the sensitivity and specificity of one study, the black line its confidence interval. TP: true-positive; FP:
false-positive; FN: false-negative; TN: true-negative.
 
Xpert MTB/RIF as a screening test in people residing in prisons,
irrespective of tuberculosis symptoms
Two studies evaluated Xpert MTB/RIF as a screening test for
pulmonary tuberculosis in persons residing in prisons. Xpert MTB/
RIF sensitivity and specificity (95% CI) were 53% (34 to 72) and 99%
(98 to 100) (Al-Darraji 2016) and 91% (83 to 96) and 95% (94 to 96)
(Santos 2020), Figure 9.
Xpert MTB/RIF as a screening test in miners, irrespective of
tuberculosis symptoms
One study evaluated Xpert MTB/RIF as a screening test for
pulmonary tuberculosis in miners (Dorman 2012). Xpert MTB/RIF
sensitivity and specificity (95% CI) were 63% (55 to 70) and 100%
(99 to 100), Figure 9.
Xpert MTB/RIF as a screening test in non-hospitalized people
in high-risk groups combined, irrespective of tuberculosis
symptoms
We estimated pooled sensitivity and specificity including the
five studies that evaluated Xpert MTB/RIF in household contacts,
miners, and people residing in prisons (i.e. populations that did not
exclusively include people living with HIV and inpatient settings)
(Al-Darraji 2016; Beyanga 2018; Dorman 2012; Ntinginya 2012;
Santos 2020). Xpert MTB/RIF pooled sensitivity and specificity (95%
CrI) were 69.4% (47.7 to 86.2) and 98.8% (97.2 to 99.5), (5 studies,
8956 participants, 337 (3.8%) with tuberculosis), Table 1, Figure 8.
Xpert MTB/RIF as a screening test in patients admitted to the
hospital, irrespective of tuberculosis symptoms
Two studies evaluated Xpert MTB/RIF as a screening test for
pulmonary tuberculosis in persons admitted to the hospital. Xpert
MTB/RIF sensitivity and specificity (95% CI) were 79% (60 to 92) and
95% (88 to 98) (Heidebrecht 2016) and 86% (80 to 91) and 95% (93 to
97) (O'Grady 2012), Figure 9. In Heidebrecht 2016, 62% of patients
had HIV and in O'Grady 2012, 71% of patients had HIV.
Xpert MTB/RIF and Xpert Ultra as a screening test in the general
population, irrespective of tuberculosis symptoms
We did not identify any studies that evaluated Xpert MTB/RIF or
Xpert Ultra as a screening test in general populations, irrespective
of signs or symptoms of tuberculosis.
Xpert MTB/RIF and Xpert Ultra as screening tests for rifampicin
resistance
Xpert MTB/RIF as a screening test for rifampicin resistance
Three studies evaluated Xpert MTB/RIF as a screening test for
rifampicin resistance (Al-Darraji 2013; Lawn 2011; O'Grady 2012).
One study reported zero rifampicin-resistant results and hence,
sensitivity was not estimable (Al-Darraji 2013). Sensitivity (95% CI)
was 100% (40 to 100) in Lawn 2011 and 81% (54 to 96) in O'Grady
2012; specificity ranged from 94% to 100%, Figure 10.
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Figure 10.   Forest plots of Xpert MTB/RIF sensitivity and specificity for rifampicin resistance, in people irrespective
of tuberculosis symptoms. The squares represent the sensitivity and specificity of one study, the black line its
confidence interval. TP: true-positive; FP: false-positive; FN: false-negative; TN: true-negative.
 
Xpert Ultra as a screening test for rifampicin resistance
We did not identify any studies that evaluated Xpert Ultra as a
screening test for detection of rifampicin resistance.
D I S C U S S I O N
Summary of main results
This Cochrane Review summarizes the current literature on the
accuracy of Xpert MTB/RIF and Xpert Ultra as screening tests
for pulmonary tuberculosis and rifampicin resistance in adults,
irrespective of signs and symptoms of tuberculosis. We identified 21
studies: 18 studies (13,114 participants) evaluated Xpert MTB/RIF
as a screening test for pulmonary tuberculosis and one study (571
participants) evaluated both Xpert MTB/RIF and Xpert Ultra. Three
studies (159 participants) evaluated Xpert MTB/RIF for rifampicin
resistance.
• As a screening test for pulmonary tuberculosis in people living
with HIV, Xpert MTB/RIF pooled sensitivity and specificity (95%
CrI) were 61.8% (53.6 to 69.9) and 98.8% (98.0 to 99.4), Summary
of findings 1.
• As a screening test for pulmonary tuberculosis in people living
with HIV (one study), Xpert Ultra sensitivity and specificity (95%
CI) were 69% (57 to 80) and 98% (97 to 99), Summary of findings
1.
• As a screening test for pulmonary tuberculosis in non-
hospitalized people in high-risk groups, Xpert MTB/RIF pooled
sensitivity and specificity (95% CrI) were 69.4% (47.7 to 86.2) and
98.8% (97.2 to 99.5), Summary of findings 1.
• As a screening test for rifampicin resistance, Xpert MTB/RIF
sensitivity was 81% and 100%, and specificity was 94% to 100%,
Summary of findings 2.
Xpert MTB/RIF as a screening test for pulmonary tuberculosis
in people living with HIV
Results of these studies indicate that, in theory, for a population
of 1000 people where 50 have tuberculosis on culture, 40 would
be Xpert MTB/RIF-positive; of these, 9 (22%) would not have
tuberculosis (false-positives); and 960 would be Xpert MTB/
RIF-negative; of these, 19 (2%) would have tuberculosis (false-
negatives), Summary of findings 1.
Xpert Ultra as a screening test for pulmonary tuberculosis in
people living with HIV
Results of these studies indicate that, in theory, for a population of
1000 people where 50 have tuberculosis on culture, 53 would be
Xpert Ultra-positive; of these, 19 (36%) would not have tuberculosis
(false-positives); and 947 would be Xpert Ultra-negative; of these,
16 (2%) would have tuberculosis (false-negatives), Summary of
findings 1.
Xpert MTB/RIF as a screening test for pulmonary tuberculosis
in non-hospitalized people in high-risk groups
Results of these studies indicate that, in theory, for a population
of 1000 people where 10 have tuberculosis on culture, 19 would
be Xpert MTB/RIF-positive; of these, 12 (63%) would not have
tuberculosis (false-positives); and 981 would be Xpert MTB/RIF-
negative; of these, 3 (0%) would have tuberculosis (false-negatives),
Summary of findings 1.
Xpert MTB/RIF and Xpert Ultra as a screening test for pulmonary
tuberculosis in high-risk groups
Our review found that Xpert MTB/RIF and Xpert Ultra, when
used as a screening test for tuberculosis, successfully identified
tuberculosis in people who were screened, regardless of symptoms
of pulmonary tuberculosis in high-risk groups and persons
attending health facilities for reasons other than diagnosis of
tuberculosis.
The sensitivity and specificity of Xpert MTB/RIF and Xpert Ultra,
compared to the microbiological reference standard of tuberculosis
culture, was similar in people living with HIV and other high-risk
groups, when used to screen for tuberculosis, irrespective of the
presence of signs and symptoms.
Current WHO and national guidelines recommend screening
people living with HIV for tuberculosis symptoms and reserve
diagnostic testing for people with symptoms. In this review, we
evaluated two subgroups of studies of people living with HIV:
studies in which 50% or more participants had tuberculosis
symptoms, and studies in which less than 50% of participants had
tuberculosis symptoms. While we did not identify any studies using
Xpert MTB/RIF to screen entirely asymptomatic people living with
HIV for tuberculosis, and are thus unable to estimate Xpert MTB/
RIF accuracy in people living with HIV without symptoms, evidence
from the subgroup analysis suggests that there is little diJerence
in the accuracy of the Xpert test in heavily symptomatic versus less
symptomatic populations of people living with HIV. The observed
prevalence of pulmonary tuberculosis was substantially higher in
the high symptom prevalence subgroup of studies compared to
the low symptom prevalence subgroup of studies (15.1% versus
3.2%), but the sensitivity and specificity of Xpert MTB/RIF were not
meaningfully diJerent in each subgroup.
We recognize that patient-important outcomes including the eJect
of the use of Xpert MTB/RIF and Xpert Ultra for screening on
treatment initiation, cure, mortality, and community incidence are
important to patients, clinicians, and decision-makers. However,
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evaluating such outcomes would have required a diJerent
methodology than this study, which focused on test accuracy in
the application of screening irrespective of symptoms. We did not
identify any studies that assessed both accuracy with a tuberculosis
culture reference standard and people-important outcomes. The
ACT3 study in Viet Nam (Marks 2019) was a community-randomized
trial evaluating the eJect of screening for tuberculosis using Xpert
MTB/RIF in adults 15 years and older, irrespective of signs and
symptoms of tuberculosis, on the prevalence of tuberculosis.
Tuberculosis culture was performed on specimens testing positive
by Xpert MTB/RIF. The study found 94 positive Xpert MTB/RIF results
among 41,680 adults tested in the control arm; tuberculosis culture
was positive in 49 of the positive Xpert MTB/RIF results for a
positive predictive value of 52%. In the intervention communities
of 42,150 adults, only 53 cases were detected by Xpert MTB/
RIF (33 culture-positive), a significant reduction in tuberculosis
prevalence. Though we were unable to include this study in our
review, as the reference microbiological standard (tuberculosis
culture) was not systematically performed with every Xpert MTB/
RIF test, the ACT3 study is an important contribution to the
evidence on use of Xpert MTB/RIF in population-based screening
and the eJect on patient-important outcomes.
There is increasing interest in using Xpert MTB/RIF and Xpert
Ultra for population-based screening for tuberculosis, such as
for national prevalence surveys. Recent national tuberculosis
prevalence surveys including in Vietnam (Nguyen 2020), Kenya
(Enos 2018), and Bangladesh (WHO Consolidated Guidelines
(Module 3) 2020) employed screening strategies with Xpert MTB/
RIF or Xpert Ultra and reference testing with mycobacterial
culture; prevalence surveys in South Africa, Zambia, and Myanmar
employed Xpert Ultra and culture for reference testing (WHO
Consolidated Guidelines (Module 3) 2020) . However, all prevalence
surveys we identified employed Xpert MTB testing only for
persons with radiographic signs and/or symptoms of tuberculosis,
thus we were unable to determine the screening accuracy of
these molecular tests in general population screening in persons
irrespective of signs and symptoms of tuberculosis. This is an
important limitation of the review.
Decisions of how and where to implement Xpert MTB/RIF and
Xpert Ultra for tuberculosis screening in persons irrespective
of symptoms require, in addition to concerns of test accuracy
as reviewed here, careful consideration of resource utilization
requirements and cost-eJectiveness of these tests, which are highly
dependent on the setting, population, and underlying prevalence
of tuberculosis in the population. While there are substantial data
supporting the cost-eJectiveness for use of Xpert MTB/RIF and
Xpert Ultra as an initial diagnostic test in symptomatic individuals
presenting to a healthcare facility in high-burden settings (WHO
2016), there is scarce published evidence for cost-eJectiveness
of these tests when used for screening people irrespective of
signs and symptoms of tuberculosis. Communities and populations
diJer in how they can access rapid molecular diagnostic tests for
tuberculosis: when provided in a centralized fashion in a healthcare
or other facility-based setting (e.g. primary care clinics providing
services to people living with HIV, inpatient hospital facilities,
prison facilities, large mining complexes), fewer resources are
needed to bring the tests in proximity to people being screened.
Screening becomes much more resource-intensive when delivered
in decentralized, community-based or household contact-tracing
settings, but conversely these settings may be where the majority
of undetected tuberculosis cases may be found, and consequently
the impact on community transmission the highest.
Strengths and weaknesses of the review
Completeness of evidence
The findings in this review are based on comprehensive searching,
strict selection criteria, and standardized data extraction. We
corresponded with study authors to obtain additional data and
information that was missing from the papers. The search strategy
included studies published in all languages. We acknowledge that
we may have missed studies despite the comprehensive search;
however, we think it unlikely that the findings would have changed.
Accuracy of the reference standards used
Culture is regarded as the best available reference standard for the
bacteriological confirmation of pulmonary tuberculosis and was
the reference standard for tuberculosis in this review. Liquid culture
is considered to be more sensitive than solid culture (Lewinsohn
2017). In this review 17 (85%) studies used liquid culture as the
reference standard.
Quality and quality of reporting of the included studies
All studies used consecutive or random selection of participants
and interpreted the reference standard results without knowledge
of index test results. Xpert results are generated automatically,
without requiring operator interpretation. Studies were generally
well reported, although we corresponded with several authors for
missing information.
Applicability of findings to the review question
For screening for pulmonary tuberculosis, we had low concern
for applicability because in most studies, participants represented
a population that was selected for tuberculosis screening in
community settings or primary care centres. FiLeen studies (75%)
were conducted in high tuberculosis burden settings and hence the
results may not be applicable to other settings. We only identified
one study that evaluated Xpert Ultra and were therefore unable
to compare test accuracy with that of Xpert MTB/RIF, a secondary
objective of the review. The one study of Xpert Ultra was conducted
in people living with HIV in South Africa, hence applicability to other
settings comes with some uncertainty.
For screening for detection of rifampicin resistance detection, of
the three included studies we were unclear about the applicability
of one study (33%) because this study evaluated the test in adult
medical inpatients at a tertiary hospital, rather than a community
setting or primary care centre.
We did not identify any studies that screened other groups at high
risk for tuberculosis that met inclusion criteria for this review, which
included the concomitant use of culture as a reference standard.
These populations include people experiencing homelessness,
people with diabetes mellitus, people who abuse alcohol, people
who smoke, and healthcare workers. We did not identify any studies
that conducted general population-wide screening for tuberculosis
(e.g. national prevalence surveys) that met inclusion criteria for this
review. This is an important limitation of the review.
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A U T H O R S '   C O N C L U S I O N S
Implications for practice
Of the high-risk groups evaluated, Xpert MTB/RIF applied as a
screening test was accurate for tuberculosis in high tuberculosis
burden settings. Sensitivity and specificity were similar in people
living with HIV and non-hospitalized people in high-risk groups. In
people living with HIV, Xpert Ultra sensitivity was slightly higher
than that of Xpert MTB/RIF and specificity similar. As there was
only one study of Xpert Ultra in this analysis, results should be
interpreted with caution. There were no studies that evaluated the
tests in people with diabetes mellitus and other groups considered
at high risk for tuberculosis, or in the general population.
Implications for research
Several high-risk groups were considered that were not
represented in any studies in this review, but evidence of the
performance of Xpert MTB/RIF, Xpert Ultra, and other rapid
molecular tests will be important to inform their use as screening
tests for tuberculosis. In particular, priority populations for
research are those in whom signs and symptoms of tuberculosis
are less sensitive for tuberculosis or in whom the consequences
of a missed diagnosis of tuberculosis are particularly severe,
such as pregnant women, people with diabetes mellitus, and
people who smoke tobacco. Only one study using Xpert Ultra
(in people living with HIV) contributed evidence to this review,
and additional studies of the accuracy of Xpert Ultra measured
against tuberculosis culture in screening people irrespective of
symptoms, with particular attention to false-positives, are needed
to understand the implications of Xpert Ultra as a screening test.
Operational research is needed to optimise the implementation
of these tests for use in community settings, ensuring appropriate
allocation of resources to enable test delivery, and to understand
how use of the tests for screening aJects the clinically meaningful
outcomes of tuberculosis treatment initiation and cure, and eJects
on local epidemiology. If data are available, future reviews should
assess the accuracy of a class of technologies, rather than a test
from a single manufacturer.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: not reported; HIV-positive prison-
ers were screened
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Age: mean 37 years (standard deviation (SD) 6.6)
Sex, female: 10%
HIV infection: 100%
History of TB: 29%
Sample size: 125
Clinical setting: outpatient, point of care
Laboratory level: other, prison
Country: Malaysia
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 12.0%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Speciation: yes
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960, MTBDR-
plus for confirmation






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
Al-Darraji 2013  (Continued)
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DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: prisoners were screened irre-
spective of s/sx; 59% reported at least 1 WHO sx
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History of TB: 12%
Sample size: 442
Clinical setting: outpatient, prison, point of care
Laboratory level: other, prison
Country: Malaysia
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 6.8%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Speciation: yes
Flow and timing  
Comparative  
Notes 4 patients with Xpert MTB/RIF+ results had neg culture results,




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Al-Darraji 2016  (Continued)
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Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: HIV-positive people screened for
TB irrespective of symptoms
Age: 18 years and older, median 32 years (IQR 28 to 40)
Sex, female: 59%
HIV infection: 100%
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World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 15.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Speciation: yes
Flow and timing  
Comparative  
Notes 2% of participants were on anti-TB treatment for up to 2 weeks -




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Balcha 2014  (Continued)
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Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive enrolment, prospective data collec-
tion
Patient characteristics and setting Presenting signs and symptoms: participants were contacts of 93
pulmonary TB patients, irrespective of symptoms
Age: all ages, median 22 years (IQR 15 to 37)
Sex, female: 57%
HIV infection: unknown





World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 4%
Beyanga 2018 
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Index tests Index: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: LJ
Speciation: yes
Flow and timing  
Comparative  





Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Beyanga 2018  (Continued)
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Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? No    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults screened for
pulmonary TB irrespective of symptoms
Age: 18 years and older, median 38 years (IQR 31 to 45)
Sex, female: 64%
HIV infection: 100%
History of TB: 6%
Sample size: 195
Clinical setting: both outpatient and inpatient
Laboratory level: central
Country: Ghana
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 17.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Bjerrum 2016 
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Speciation: yes






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Bjerrum 2016  (Continued)
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Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: miners attending occupational
health services for annual examination, irrespective of signs and
symptoms
Age: 43 years (34-49)
Sex, female: 6.1%
HIV infection: 14% positive, 50% unknown
History of TB: 12%
Sample size: 6893
Clinical setting: outpatient (mine)
Laboratory level: intermediate
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: MGIT 960
Speciation: yes
Flow and timing 272/6893 (3.9%) specimens had invalid Xpert MTB/RIF or contam-





Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
or symptoms (Review)














Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Dorman 2012  (Continued)
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Patient Sampling Cross-sectional, consecutive enrolment, prospective data collec-
tion
Patient characteristics and setting Presenting signs and symptoms: irrespective of symptoms. 45%
had signs and symptoms of TB.
Age: adults median 41 years (IQR 31-57)
Sex, female: 65%
HIV infection: 62%
History of TB: 23%
Sample size: 215
Clinical setting: inpatient medical ward
Laboratory level: intermediate
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 23%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960 and Middlebrook
Speciation: yes
Flow and timing Of 215 patients with Xpert, only 125 also had culture performed
(on 2nd sample). 2nd sample for reference testing unobtainable
for nearly 40% of participants. Total data come from 125 pairs.
Comparative  





Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Heidebrecht 2016 
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Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? No    
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Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: ART-naïve people presenting for
initiation of HIV care
Age: 16 years and older, median 34 years (IQR 29 to 40)
Sex, female: 49%
HIV infection: 100%





World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 18.6%
Index tests Index: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Speciation: yes
Flow and timing  
Comparative  
Notes The paper states that outpatients in this cohort were likely to have




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Henostroza 2016  (Continued)
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Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: newly diagnosed HIV+ patients,
irrespective of symptoms. 63% had >=1 WHO symptom
Age: adults >=18 years, mean 42 (SD 10)
Sex, female: 30%
Kempker 2019 
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HIV infection: 100%, median CD4 count: 122 cells/mm3
History of TB: 3%




World Bank Income Classification: upper-middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 12%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ solid culture
Speciation: yes






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Kempker 2019  (Continued)
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Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: none reported. HIV-infected
women accessing prevention of mother-to-child transmission ser-
vices as part of antenatal care were eligible
Age: 16 years and older, median 25 years (IQR 22 to 30)
Sex, female: 100%
HIV infection: 100%
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Country: Kenya
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 2.4%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Speciation: yes






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Unclear    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
LaCourse 2016  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: HIV-infected people with ad-
vanced immunodeficiency, irrespective of symptoms (most had 1
or more of the following TB symptoms: current cough, fever, night
sweats, or weight loss)
Age: median 34 years (IQR 28 to 41)
Sex, female: 65.4%
HIV infection: 100%
History of TB: 26.5%
Sample size: 394
Clinical setting: HIV anti-retroviral clinic; all participants were
screened for TB
Laboratory level: central
Country: South Africa, Cape Town
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
Lawn 2011 
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
or symptoms (Review)










Cochrane Database of Systematic Reviews
High TB/HIV burden country: yes
TB incidence rate: 993 per 100,000
MDR-TB prevalence: % MDR-TB among new TB cases = 0.9%
(Source: survey in Western Cape Province, 2002) and among retreat-
ment cases = 4.0% (Source: survey in Western Cape Province, 2002)
Prevalence of TB cases in the study: 18.3%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Target condition: rifampicin resistance
Reference standard for rifampicin resistance: culture-based DST
(MGIT 960)
Flow and timing  
Comparative  
Notes Lawn 2011 determined Xpert MTB/RIF accuracy for detection of ri-
fampicin resistance, with respect to culture-based drug susceptibil-
ity testing. Xpert MTB/RIF accuracy for detection of TB, with respect




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting
do not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or in-
terpretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Lawn 2011  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpre-
tation have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data collec-
tion
Patient characteristics and setting Presenting signs and symptoms: HIV-infected people with advanced im-
munodeficiency, irrespective of symptoms (most had 1 or more of the fol-
lowing TB symptoms: current cough, fever, night sweats, or weight loss)
Age: median 34 years (IQR 28 to 41)
Sex, female: 65.4%
HIV infection: 100%
History of TB: 26.5%
Sample size: 394
Clinical setting: HIV anti-retroviral clinic; all participants were screened for
TB
Laboratory level: central
Country: South Africa, Cape Town
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Lawn 2012 
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
or symptoms (Review)
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TB incidence rate: 993 per 100,000
MDR-TB prevalence: % MDR-TB among new TB cases = 0.9% (Source: sur-
vey in Western Cape Province, 2002) and among retreatment cases = 4.0%
(Source: survey in Western Cape Province, 2002)
Prevalence of TB cases in the study: 18.3%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Speciation: yes
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing  
Comparative  
Notes This study evaluated the use of Xpert MTB/RIF to screen HIV-infected peo-
ple with advanced immunodeficiency enrolling in antiretroviral therapy
services regardless of symptoms, although most participants in the study
had TB symptoms. Of 3 participants with apparent false-positive Xpert
MTB/RIF results, on follow-up 2 had overt pulmonary and systemic symp-
toms suggestive of TB and improved on anti-TB treatment. The 3rd partici-
pant was lost to follow-up. Median CD4 cell count, 171 cells/ml; IQR 102 to
236
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced
bias?
  Low risk  
Are there concerns that the included patients and
setting do not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Lawn 2012  (Continued)
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Could the conduct or interpretation of the index test
have introduced bias?
  Low risk  
Are there concerns that the index test, its conduct,
or interpretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its in-
terpretation have introduced bias?
  Low risk  
Are there concerns that the target condition as de-
fined by the reference standard does not match the
question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: HIV-infected people at the time
of HIV diagnosis, irrespective of symptoms (41.3% had 1 or more
TB symptoms: current cough, fever, night sweats, or weight loss)
Age: mean 35 years (SD 14)
Sex, female: 56.4%
HIV infection: 100% (median CD4 328, IQR 195 to 505)
History of TB: 1.6%
Sample size: 91
Clinical setting: home-based HIV counselling and testing
Lopez-Varela 2019 
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
or symptoms (Review)
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Laboratory level: intermediate
Country: Mozambique
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
TB incidence rate: 847 per 100,000
Prevalence of TB cases in the study: 4.4%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: liquid culture
Speciation: yes






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
Lopez-Varela 2019  (Continued)
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DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: 16 years and older, mean 42 years
Sex, female: 55%
HIV infection: 100%





World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Mollel 2017 
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Prevalence of TB cases in the study: 13.0%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Speciation: not reported






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Unclear    
Mollel 2017  (Continued)
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Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional study, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: household contacts enrolled irre-
spective of symptoms (15.5% reported >=1 TB symptom)
Age: age >=5, mean 26 years (SD 17.6)
Sex, female: 59.4%
HIV infection: not assessed
History of TB: 3%
Sample size: 33




World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 15% of people who produced
sputum; 2.3% of contacts overall
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: solid LJ or liquid MGIT 960
Ntinginya 2012 
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Speciation: yes
Flow and timing 219 contacts approached; only 33 (15.1%) able to produce sputum






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Ntinginya 2012  (Continued)
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Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Unclear    
Were all patients included in the analysis? No    





Patient Sampling Cross-sectional sampling, consecutive enrolment, prospective da-
ta collection
Patient characteristics and setting Presenting signs and symptoms: adult medical inpatients at ter-
tiary hospital, regardless of symptoms or admission diagnosis (on
TB treatment excluded from analysis)
Age: adults >15 years, median age 35 years (IQR 28 to 43 )
HIV infection: 71%
History of TB: unknown
Sample size: 643
Clinical setting: tertiary hospital admitted patients
Laboratory level: intermediate
Country: Zambia
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 31% of 643 patients not on
treatment
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: MGIT 960
Speciatiation: yes
Flow and timing 881 admitted patients contributed to demographics above, of
whom 643 not already on TB treatment and included in the analy-
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Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
O'Grady 2012  (Continued)
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Patient Sampling Cross-sectional study, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: HIV+ adults initiating ART, irre-




History of TB: not reported
Sample size: 571
Clinical setting: outpatient ART clinic
Laboratory level: intermediate
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 12%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: MGIT 960






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Reeve 2019a 
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Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional study, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: HIV+ adults initiating ART, irre-
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HIV infection: 100%
History of TB: not reported
Sample size: 571
Clinical setting: outpatient ART clinic
Laboratory level: intermediate
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 12%
Index tests Index test: Xpert Ultra
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: MGIT 960






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Reeve 2019b  (Continued)
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Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional study, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: Adults residing in prisons, irre-
spective of signs and symptoms. (40% of total pop reported at
least 1 sx, 80.4% of sputum providers reported at least 1 symp-
tom)
Sex, female: 0%
HIV infection: not reported (2% in TB+)
History of TB: 8% of screened population
Sample size: N = 5387; N = 1385 with both Xpert & culture per-
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World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 7% (of persons tested/pro-
ducing sputum)
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: TB culture (both MGIT & LJ available at refer-
ence lab)
Flow and timing  
Comparative  
Notes 3919 unable to produce sputum. 1467 (27%) provided sputum,
1385 participants had both Xpert & culture performed. Invalid/not
done tests not included in analysis. Does not specify whether Mtb




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified?      
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Santos 2020  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? No    





Patient Sampling Cross-sectional study, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: irrespective of symptoms
Age: 18 years and older, median 30 (26-46)
Sex, female: 0%
HIV infection: 100%
History of TB: 9%
Sample size: 635
Clinical setting: outpatient IVDU treatment centre
Laboratory level: intermediate
Country: Pakistan
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: no
Tahseen 2018 
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Prevalence of TB cases in the study: 13.0%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard: LJ and MGIT 960
Speciaiton: yes







Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Tahseen 2018  (Continued)
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Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional design, consecutive enrolment, prospective data
collection
Patient characteristics and setting Presenting signs and symptoms: HIV-positive people initiating an-
tiretroviral therapy
Age: 18 years and older, median 33 years (IQR 27 to 40)
Sex, female: 53%
HIV infection: 100%
History of TB: 4%
Sample size: 1177
Clinical setting: outpatient HIV/AIDS clinics
Laboratory level: central
Country: Uganda
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 13.8%
Index tests Index test: Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Yoon 2017 
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Speciation: yes






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Yoon 2017  (Continued)
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Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Yoon 2017  (Continued)
ART: antiretroviral therapy; IQR: interquartile range; MDR: multidrug-resistant; MGIT: Mycobacteria Growth Indicator Tube; SD: standard
deviation; TB: tuberculosis.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adams 2015 persons not screened irrespective of symptoms
Adejumo 2018 persons not screened irrespective of symptoms
Adetunji 2019 no microbiological reference standard (TB culture)
Agizew 2017 persons not screened irrespective of symptoms
Aia 2016 persons not screened irrespective of symptoms
Antonenka 2013 persons not screened irrespective of symptoms
Ardizzoni 2015 persons not screened irrespective of symptoms
Ardizzoni 2020 persons not screened irrespective of symptoms
Assefa 2019 no microbiological reference standard (TB culture)
Auld 2016a not original research
Auld 2016b persons not screened irrespective of symptoms
Auld 2020 no microbiological reference standard (TB culture)
Awan 2018 persons not screened irrespective of symptoms
Ayala 2016 persons not screened irrespective of symptoms
Bablishvili 2015 persons not screened irrespective of symptoms
Bacells 2016 Xpert used on a non-respiratory sample
Balcha 2014a duplicate data from another study
Balcha 2015 duplicate data from another study
Basir 2019 no microbiological reference standard (TB culture)
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Study Reason for exclusion
Bassett 2019 no microbiological reference standard (TB culture)
Benjamin 2019 persons not screened irrespective of symptoms
Bhardwaj 2019 persons not screened irrespective of symptoms
Bjerrum 2015 number of positive tests not reported
Blakemore 2011 persons not screened irrespective of symptoms
Boum 2016 persons not screened irrespective of symptoms
Byashalira 2019 persons not screened irrespective of symptoms
Calligaro 2017 data not disaggregated on persons screened with or regardless of symptoms
Carmone 2017 no microbiological reference standard (TB culture)
Cavanaugh 2016 data insufficient for 2x2 table
Celik 2015 persons not screened irrespective of symptoms
Charoensook 2018 persons not screened irrespective of symptoms
Chry 2020 persons not screened irrespective of symptoms
Chumpa 2020 persons not screened irrespective of symptoms
Deshmukh 2020 persons not screened irrespective of symptoms
Ekeke 2020 persons not screened irrespective of symptoms
Farra 2017 persons not screened irrespective of symptoms
Floridia 2017 no microbiological reference standard (TB culture)
Gautam 2019 persons not screened irrespective of symptoms
Gelalcha 2017 persons not screened irrespective of symptoms
Gizachew 2017 persons not screened irrespective of symptoms
Gupta-Wright 2018 no microbiological reference standard (TB culture)
Gursoy 2016 persons not screened irrespective of symptoms
Habeenzu 2017 persons not screened irrespective of symptoms
Habte 2016 persons not screened irrespective of symptoms
Hanifa 2016 no microbiological reference standard (TB culture)
Head 2019 persons not screened irrespective of symptoms
Hiruy 2018 persons not screened irrespective of symptoms
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Study Reason for exclusion
Ho 2016 no microbiological reference standard (TB culture)
Hosseinipour 2016 no microbiological reference standard (TB culture)
Huang 2018 persons not screened irrespective of symptoms
Huerga 2020 persons not screened irrespective of symptoms
Huh 2019 Xpert used on a non-respiratory sample
Kamenska 2019 persons not screened irrespective of symptoms
Kerkhoff 2014 Xpert used on a non-respiratory sample
Kurbaniyazova 2017 data not disaggregated on persons screened with or regardless of symptoms
Kuyinu 2018 persons not screened irrespective of symptoms
LaCourse 2014 paediatric population
LaCourse 2018 paediatric population
Lawn 2012a duplicate data from another study
Lawn 2012b duplicate data from another study
Lawn 2013 duplicate data from another study
Lawn 2015 data insufficient for 2x2 table
Lawn 2017 duplicate data from another study
Lebina 2016 no microbiological reference standard (TB culture)
Lima 2020 persons not screened irrespective of symptoms
Luo 2019 persons not screened irrespective of symptoms
Maria 2018 persons not screened irrespective of symptoms
Marks 2019 no microbiological reference standard (TB culture)
Marlowe 2011 persons not screened irrespective of symptoms
Mbatchou 2019 data insufficient for 2x2 table
Mbu 2018 data insufficient for 2x2 table
Meng 2017 persons not screened irrespective of symptoms
Metcalfe 2015 persons not screened irrespective of symptoms
Metcalfe 2016 persons not screened irrespective of symptoms
Miller 2011 persons not screened irrespective of symptoms
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Study Reason for exclusion
Mishra 2020 persons not screened irrespective of symptoms
Modi 2016 data insufficient for 2x2 table
Morishita 2017 persons not screened irrespective of symptoms
Nathavitharana 2017 persons not screened irrespective of symptoms
Nicol 2018 persons not screened irrespective of symptoms
Nikolayevskyy 2019 persons not screened irrespective of symptoms
Ou 2019 persons not screened irrespective of symptoms
Ozkutuk 2014 persons not screened irrespective of symptoms
Parcell 2017 persons not screened irrespective of symptoms
Park 2013 persons not screened irrespective of symptoms
Pimkina 2015 persons not screened irrespective of symptoms
Ramamurthy 2016 persons not screened irrespective of symptoms
Reepalu 2016 data insufficient for 2x2 table
Reis 2019 persons not screened irrespective of symptoms
Sarinoglu 2020 persons not screened irrespective of symptoms
Semitala 2019 no microbiological reference standard (TB culture)
Shah 2019 paediatric population
Sun 2019 persons not screened irrespective of symptom
Teo 2011 persons not screened irrespective of symptom
Trajman 2014 persons not screened irrespective of symptom
van Kampen 2015 persons not screened irrespective of symptom
Van Rie 2011 not original research
Yasemin 2019 persons not screened irrespective of symptom
Yoon 2019 duplicate data from another study
 
 
D A T A
Presented below are all the data for all of the tests entered into the review.
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Table Tests.   Data tables by test
Test No. of studies No. of participants
1 Xpert MTB/RIF, HIV positive, irrespective of TB symptoms 12 4775
2 Xpert Ultra, HIV, irrespective of TB symptoms 1 571
3 Xpert MTB/RIF, household contacts, irrespective of TB symptoms 2 508
4 Xpert MTB/RIF, prisoners, irrespective of TB symptoms 2 1827
5 Xpert MTB/RIF, miners, irrespective of TB symptoms 1 6621
6 Xpert MTB/RIF, admitted patients, irrespective of TB symptoms 2 768
7 Xpert MTB/RIF, all high-risk groups 18 13114
8 Xpert MTB/RIF for rifampicin resistance 3 159
 
 
Test 1.   Xpert MTB/RIF, HIV positive, irrespective of TB symptoms
 
 
Test 2.   Xpert Ultra, HIV, irrespective of TB symptoms
 
 
Test 3.   Xpert MTB/RIF, household contacts, irrespective of TB symptoms
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Test 4.   Xpert MTB/RIF, prisoners, irrespective of TB symptoms
 
 
Test 5.   Xpert MTB/RIF, miners, irrespective of TB symptoms
 
 
Test 6.   Xpert MTB/RIF, admitted patients, irrespective of TB symptoms
 
 
Test 7.   Xpert MTB/RIF, all high-risk groups
 
 
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
or symptoms (Review)










Cochrane Database of Systematic Reviews
Test 8.   Xpert MTB/RIF for rifampicin resistance
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Table 1.   Xpert MTB/RIF as a screening test for pulmonary tuberculosis in people irrespective of tuberculosis signs and symptoms, against culture 
aHigh-risk groups include household contacts, people residing in prisons, and miners.
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A P P E N D I C E S




#1 Search Tuberculosis or MDR-TB or XDR-TB or tuberculous Field: Title/Abstract
#2 Search “Mycobacterium tuberculosis” [Mesh]
#3 Search "Tuberculosis"[Mesh] or ("Tuberculosis, Multidrug-Resistant"[Mesh]) OR "Extensively Drug-
Resistant Tuberculosis"[Mesh]
#4 Search ((#3) OR #2) OR #1
#5 Search Xpert* or GeneXpert or Ultra or cepheid Field: Title/Abstract
#6 Search "near* patient*" or near-patient Field: Title/Abstract
#7 Search (#6) OR #5
#8 Search "active case" Field: Title/Abstract
#9 Search "case finding" Field: Title/Abstract
#10 Search prevalence Field: Title/Abstract
#11 Search Asymptomatic Field: Title/Abstract
#12 Search comorbidity or co-morbidity Field: Title/Abstract
#13 Search screening Field: Title/Abstract
#14 Search Detect* or missed or undetect* or undiagnosed Field: Title/Abstract
#15 Search ((((((#14) OR #13) OR #12) OR #11) OR #10) OR #9) OR #8
#16 Search (#4) AND #7 AND #15
 
 
Database: Embase 1947-present, updated daily
Search Strategy:
--------------------------------------------------------------------------------
1 (tuberculosis or TB).mp.
2 Tuberculosis, Multidrug-Resistant/ or Extensively Drug-Resistant Tuberculosis/ or Tuberculosis/ or tuberculosis.mp. or Mycobacterium
tuberculosis/
3 (MDR-TB or XDR-TB).mp.
4 1 or 2 or 3
5 Xpert* MTB RIF.ti. or Xpert* MTB RIF.ab.
6 (Xpert* or GeneXpert or cepheid).mp.
7 (near* patient or near-patient).ti. or (near* patient or near-patient).ab.
8 5 or 6 or 7
9 4 and 8
10 detection.mp.
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11 diagnostic error/ or missed.mp.
12 (undetected or undiagnosed).mp.
13 asymptomatic.mp.
14 comorbidity.mp. or comorbidity/
15 prevalence/
16 active case finding.mp. or case finding/
17 10 or 11 or 12 or 13 or 14 or 15 or 16
18 9 and 17
Web of Science
 
# 3 #2 AND #1
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 2 TOPIC: (asymptomatic or undetected or undiagnosed) OR TOPIC: ("case find-
ing" or prevalence or comorbidity)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 1 TOPIC: (tuberculosis OR tb OR mycobacterium) AND TOPIC: (xpert* OR genex-
pert OR cepheid)




( TITLE-ABS-KEY ( tuberculosis OR tb OR mycobacterium ) AND TITLE-ABS-KEY ( ( xpert* OR genexpert OR cepheid ) ) AND TITLE-ABS-KEY
( asymptomatic OR undetected OR undiagnosed OR "case finding" OR prevalence OR comorbidity ) )
LILACS
(tuberculosis OR TB OR mycobacterium) (Words) AND (xpert$ OR Genexpert OR Cepheid) (Words)
Cochrane Infectious Diseases Specialized Register
(tuberculosis or TB) and (xpert* or Genexpert or Cepheid)
Clinicaltrials.gov, WHO ICTRP, ISRCTN:
Tuberculosis and Genexpert
Tuberculosis and Xpert
ProQuest Dissertations & Theses
tuberculosis and (Xpert or genexpert)
Appendix 2. QUADAS-2
In QUADAS-2, we assessed methodological quality separately for each of the objectives, Xpert for pulmonary tuberculosis detection and
Xpert for rifampicin resistance detection.
Domain 1: patient selection
Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: was a consecutive or random sample of patients enrolled? We answered ‘yes' if the study enrolled a consecutive or
random sample of eligible patients; ‘no' if the study selected patients by convenience; and ‘unclear' if the study did not report the manner
of patient selection or we could not tell.
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Signalling question 2: did the study avoid inappropriate exclusions? We answered ‘yes' if the study included all individuals in the general
population or the high-risk group considered for tuberculosis screening. We answered ‘no' if the study primarily or exclusively included
individuals with a history of tuberculosis; individuals who had undergone previous treatment (retreatment patients); or those with signs
and symptoms of tuberculosis. We answered ‘unclear' if we could not tell.
Applicability: are there concerns that the included patients and setting do not match the review question?
We were interested in how Xpert MTB/RIF or Xpert Ultra performed in patients who were evaluated as they would be in the settings of
intended use. We answered ‘low concern' if the study population resembled a population that was selected for tuberculosis screening in
community settings or primary care centres. We answered ‘high concern' if the study population does not resemble a population that was
selected for tuberculosis screening in a community setting. We answered ‘unclear concern' if there was insuJicient information to make
a decision.
Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance
Domain 1: patient selection is the same as for MTB/RIF or Xpert Ultra for detection of pulmonary tuberculosis.
Domain 2: index test
Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: were the index test results interpreted without knowledge of the results of the reference standard? We answered this
question ‘yes' for all studies because Xpert test results were automatically generated and the user was provided with printable test results.
Thus, there is no room for subjective interpretation of test results.
Signalling question 2: if a threshold was used, was it prespecified? The threshold was prespecified in all versions of Xpert. We answered this
question ‘yes' for all studies.
For risk of bias, we judge ‘low concern' for all studies.
Applicability: are there concerns that the index test, its conduct, or its interpretation diJer from the review question? Variations in test
technology, execution, or interpretation may aJect estimates of the diagnostic accuracy of a test. All steps in the Xpert MTB/RIF and Xpert
Ultra assays are completely automated and self-contained following sample loading. We answered ‘low concern' if the index test was
performed as recommended by the manufacturer, which we had anticipated would be true for most studies. We answered ‘unclear concern'
if the ratio of the Xpert MTB/RIF or Xpert Ultra sample reagent: specimen volume was not 2:1 for a raw specimen or 3:1 for a sediment, as
recommended by the manufacturer.
Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance
Domain 2: index test is the same as for MTB/RIF or Xpert Ultra for detection of pulmonary tuberculosis.
Domain 3: reference standard
Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1: is the reference standard likely to correctly classify the target condition?
We answered ‘yes' for all studies, since culture as a reference standard was a criterion for inclusion in the review.
Signalling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
We answered ‘yes' if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was clear
that the reference standard was performed at a separate laboratory and/or performed by diJerent people. We answered ‘no' if the study
stated that the reference standard result was interpreted with knowledge of the Xpert MTB/RIF or Xpert Ultra test result. We answered
‘unclear' if we could not tell.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question? We answered
‘high concern' if included studies did not speciate mycobacteria isolated in culture; ‘low concern' if speciation was performed; and ‘unclear
concern' if we could not tell.
Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: is the reference standard likely to correctly classify the target condition?
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We answered ‘yes' if either culture-based drug susceptibility testing (DST) or line probe assay (such as MTBDRplus) was used. These are
the criteria for inclusion for this objective of the review.
Signalling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
We answered ‘yes' if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was clear
that the reference standard was performed at a separate laboratory and/or performed by diJerent people. We answered ‘no' if the study
stated that the reference standard result was interpreted with knowledge of the Xpert MTB/RIF or Xpert Ultra test result. We will answer
‘unclear' if we could not tell.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question? We judged
applicability to be of ‘low concern' for those studies evaluating Xpert MTB/RIF or Xpert Ultra for rifampicin resistance because these
specimens had already been identified as Mycobacterium tuberculosis positive.
Domain 4: flow and timing
Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis detection
Risk of bias: could the patient flow have introduced bias?
Signalling question 1: was there an appropriate interval between the index test and reference standard? In most included studies, we
expected that specimens for Xpert MTB/RIF or Xpert Ultra and culture would be obtained at the same time, when patients were screened.
However, even if there were a delay of several days between index test and reference standard, tuberculosis is a chronic disease and we
considered misclassification of disease status to be unlikely, as long as treatment was not initiated in the interim. We answered ‘yes' if the
index test and reference standard were performed at the same time or if the time interval was less than or equal to seven days, ‘no' if the
time interval was greater than seven days, and ‘unclear' if we could not tell.
Signalling question 2: did all patients receive the same reference standard? We answered this question ‘yes' for all studies as an acceptable
reference standard (either solid or liquid culture) was specified as a criterion for inclusion in the review. However, we acknowledge that it is
possible that some specimens could undergo solid culture and others liquid culture. This could potentially result in variations in accuracy,
but we thought the variation would be minimal.
Signalling question 3: were all patients included in the analysis? We determined the answer to this question by comparing the number of
patients enrolled with the number of patients included in the 2 x 2 tables. We answered ‘yes' if the numbers matched and ‘no' if there were
patients enrolled in the study that were not included in the analysis. We answered ‘unclear' if we could not tell.
Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance
Domain 4: flow and timing is the same as for Xpert MTB/RIF or Xpert Ultra for detection of pulmonary tuberculosis.
Judgements for ‘Risk of bias' assessments for a given domain
• If we answered all signalling questions for a domain ‘yes', then we judged risk of bias as ‘low'.
• If we answered all or most signalling questions for a domain ‘no', then we judged risk of bias as ‘high'.
• If we answered only one signalling question for a domain ‘no', we discussed further the risk of bias judgement.
• If we answered all or most signalling questions for a domain ‘unclear', then we judged risk of bias as ‘unclear'.
• If we answered only one signalling question for a domain ‘unclear', we discussed further the risk of bias judgement for the domain.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Objectives: we intended to assess Xpert MTB/RIF and Xpert Ultra as screening tests for pulmonary tuberculosis in the general population,
irrespective of signs and symptoms. However, we did not identify any studies conducted in the general population.
Types of studies: We included abstracts with suJicient data to populate 2x2 contingency tables.
Statistical analysis and data synthesis: we performed a post-hoc analysis by combining several high-risk groups into a single pooled
analysis of sensitivity and specificity in adults at high risk for tuberculosis. These high-risk groups included household contacts of people
with tuberculosis, people residing in prisons, and miners. We had planned to compare the accuracy of Xpert MTB/RIF and Xpert Ultra by first
including all studies with relevant data, i.e. both indirect and direct comparisons, and then by restricting the analyses to studies that made
comparisons between Xpert MTB/RIF and Xpert Ultra in the same participants, i.e. direct comparisons. However, there were insuJicient
data to perform these comparisons. We stated in the protocol that we would provide predictive sensitivity and specificity. We did not do
this. However, instead, we estimated positive and negative predictive values at pre-specified pre-test probabilities recommended by the
WHO (0.5% and 5%) as we considered these values more useful for clinicians.
Subgroup analyses: we intended to perform subgroup analyses among studies conducted in high versus not high tuberculosis burden
countries, and similarly for high TB/HIV burden and high MDR-TB burden versus not high burden countries. However, most studies were
conducted in high burden countries, therefore we did not perform these subgroup analyses.
Sensitivity analyses: we had planned to perform sensitivity analyses limiting the analyses to studies that accounted for all participants in
the analysis, studies that used liquid culture as the reference standard, and studies where a consecutive or random sample of participants
were enrolled. However, all studies met these criteria, therefore we were unable to perform these sensitivity analyses.
Uninterpretable results: regarding uninterpretable results, in the protocol we wrote we would use a Bayesian hierarchical model for a single
proportion to estimate the pooled proportion of uninterpretable index test results. However, most studies in this review did not report
uninterpretable results, so we did not model them separately.
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Non-stigmatising language: whenever possible, we re-categorized high-risk groups using non-stigmatising language. For example, we
changed the category "homeless people" to "people experiencing homelessness."
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs
or symptoms (Review)
Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
89
